CA2389605A1 - Cholesterol reducing stanol compositions, preparation and method of use - Google Patents
Cholesterol reducing stanol compositions, preparation and method of use Download PDFInfo
- Publication number
- CA2389605A1 CA2389605A1 CA002389605A CA2389605A CA2389605A1 CA 2389605 A1 CA2389605 A1 CA 2389605A1 CA 002389605 A CA002389605 A CA 002389605A CA 2389605 A CA2389605 A CA 2389605A CA 2389605 A1 CA2389605 A1 CA 2389605A1
- Authority
- CA
- Canada
- Prior art keywords
- phytostanol
- weight percent
- group
- mixtures
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 203
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 110
- 238000000034 method Methods 0.000 title claims description 56
- 235000012000 cholesterol Nutrition 0.000 title description 47
- 238000002360 preparation method Methods 0.000 title description 8
- 239000004094 surface-active agent Substances 0.000 claims abstract description 66
- 150000002148 esters Chemical class 0.000 claims abstract description 51
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000013305 food Nutrition 0.000 claims abstract description 41
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims abstract description 31
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims abstract description 31
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 claims abstract description 25
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 claims abstract description 12
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 claims abstract description 12
- ARYTXMNEANMLMU-OZEQXKMUSA-N 5alpha-ergostan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-OZEQXKMUSA-N 0.000 claims abstract description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 50
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 29
- -1 polyoxyethylene Polymers 0.000 claims description 29
- 239000002202 Polyethylene glycol Substances 0.000 claims description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 21
- 239000005720 sucrose Substances 0.000 claims description 21
- 150000002191 fatty alcohols Chemical class 0.000 claims description 20
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 19
- 230000001906 cholesterol absorption Effects 0.000 claims description 18
- 239000002775 capsule Substances 0.000 claims description 17
- 229920000136 polysorbate Polymers 0.000 claims description 16
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims description 14
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 14
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 14
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 14
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 claims description 14
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 claims description 14
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 13
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 12
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 9
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims description 8
- DUGDSUSSAHQMFH-UHFFFAOYSA-N 2-acetyl-2-hydroxy-4-oxopentanoic acid Chemical class C(C)(=O)CC(C(=O)O)(O)C(C)=O DUGDSUSSAHQMFH-UHFFFAOYSA-N 0.000 claims description 8
- 229920005682 EO-PO block copolymer Polymers 0.000 claims description 8
- 239000001422 FEMA 4092 Substances 0.000 claims description 8
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 8
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 8
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims description 8
- 229940073143 ammoniated glycyrrhizin Drugs 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 229960000541 cetyl alcohol Drugs 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 8
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 8
- 229940113124 polysorbate 60 Drugs 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- LGJMUZUPVCAVPU-GJAZBXDESA-N poriferastan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-GJAZBXDESA-N 0.000 claims description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical class [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 8
- 229960002666 1-octacosanol Drugs 0.000 claims description 7
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 7
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 7
- 239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 claims description 7
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical group O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 7
- 229960000735 docosanol Drugs 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 7
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 7
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 7
- 229940068977 polysorbate 20 Drugs 0.000 claims description 7
- 229940101027 polysorbate 40 Drugs 0.000 claims description 7
- 229940068968 polysorbate 80 Drugs 0.000 claims description 7
- 229940113171 polysorbate 85 Drugs 0.000 claims description 7
- 235000013875 sodium salts of fatty acid Nutrition 0.000 claims description 7
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 6
- 239000005968 1-Decanol Substances 0.000 claims description 6
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 6
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000155 melt Substances 0.000 claims description 3
- 238000009490 roller compaction Methods 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims description 2
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 claims 5
- 239000003945 anionic surfactant Substances 0.000 abstract description 5
- 239000002736 nonionic surfactant Substances 0.000 abstract description 5
- 125000000129 anionic group Chemical group 0.000 abstract description 4
- 125000002091 cationic group Chemical group 0.000 abstract description 4
- 239000002888 zwitterionic surfactant Substances 0.000 abstract description 4
- 239000003093 cationic surfactant Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 235000013861 fat-free Nutrition 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 38
- 239000000843 powder Substances 0.000 description 35
- 150000003904 phospholipids Chemical class 0.000 description 27
- 239000003826 tablet Substances 0.000 description 24
- 235000010445 lecithin Nutrition 0.000 description 22
- 239000000787 lecithin Substances 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000013373 food additive Nutrition 0.000 description 19
- 239000002778 food additive Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 13
- 241000699800 Cricetinae Species 0.000 description 13
- 229930182558 Sterol Natural products 0.000 description 13
- 229940067606 lecithin Drugs 0.000 description 13
- 150000003432 sterols Chemical class 0.000 description 13
- 235000003702 sterols Nutrition 0.000 description 13
- 235000021355 Stearic acid Nutrition 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 12
- 239000008279 sol Substances 0.000 description 12
- 239000008117 stearic acid Substances 0.000 description 12
- 230000002550 fecal effect Effects 0.000 description 11
- 235000002378 plant sterols Nutrition 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000007903 gelatin capsule Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 9
- 235000010469 Glycine max Nutrition 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 229940083466 soybean lecithin Drugs 0.000 description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 8
- 229950005143 sitosterol Drugs 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000008158 vegetable oil Substances 0.000 description 8
- 229920003084 Avicel® PH-102 Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000003995 emulsifying agent Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 5
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- 229940107071 plant stanol ester Drugs 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 4
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 229940076810 beta sitosterol Drugs 0.000 description 4
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 229960005168 croscarmellose Drugs 0.000 description 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000015500 sitosterol Nutrition 0.000 description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000015111 chews Nutrition 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000011833 dog model Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000010128 melt processing Methods 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 229920000223 polyglycerol Polymers 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229940045870 sodium palmitate Drugs 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UPWGQKDVAURUGE-KTKRTIGZSA-N 2-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO UPWGQKDVAURUGE-KTKRTIGZSA-N 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 244000188595 Brassica sinapistrum Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 235000001543 Corylus americana Nutrition 0.000 description 2
- 235000007466 Corylus avellana Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N Myristoleic acid Natural products CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 2
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N ethyl stearic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- AOHAPDDBNAPPIN-UHFFFAOYSA-N myristicinic acid Natural products COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000021400 peanut butter Nutrition 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 238000009491 slugging Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010129 solution processing Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-JXMPMKKESA-N (Z)-24-ethylidenelophenol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 LPZCCMIISIBREI-JXMPMKKESA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930186217 Glycolipid Chemical group 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034203 Pectus Carinatum Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001047198 Scomberomorus semifasciatus Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001489212 Tuber Species 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000012467 brownies Nutrition 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940107170 cholestyramine resin Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000003181 co-melting Methods 0.000 description 1
- 239000008373 coffee flavor Substances 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000019221 dark chocolate Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000020351 fruit smoothie Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000020993 ground meat Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000020278 hot chocolate Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000014569 mints Nutrition 0.000 description 1
- 239000012768 molten material Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940096992 potassium oleate Drugs 0.000 description 1
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940045845 sodium myristate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- WYPBVHPKMJYUEO-NBTZWHCOSA-M sodium;(9z,12z)-octadeca-9,12-dienoate Chemical compound [Na+].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O WYPBVHPKMJYUEO-NBTZWHCOSA-M 0.000 description 1
- JUQGWKYSEXPRGL-UHFFFAOYSA-M sodium;tetradecanoate Chemical compound [Na+].CCCCCCCCCCCCCC([O-])=O JUQGWKYSEXPRGL-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Abstract
A composition comprising a mixture of a phytostanol and/or phytostanol ester and a surfactant(s). The surfactants are selected from the group consisting of anionic, cationic, nonionic, and zwitterionic surfactants. The phytostanol is selected from the group consisting of sitostanol, campestanol, 22,23 dihydrobrassicastanol, and mixtures thereof. The phytostanol esters are derivatives of the aforementioned phytostanols. The invention is also directed to a method of making the disclosed compositions, and to non-fat containing food products including the disclosed compositions.
Description
Cholesterol Reducing Stanol Compositions, Preparation and Method of Use BACKGROUND
Field of the Invention This invention relates to plant stanol compositions and its derivatives for reduction of cholesterol absorption. More particularly, the invention provides compositions containing a phytostanol and/or a phytostanol ester and surfactants) that are useful for reducing cholesterol absorption. The invention also relates to methods of preparing such compositions for reducing cholesterol absorption.
Related Background Art Cholesterol, while an essential nutrient for humans, is well known to be a leading cause of death in the United States and most countries around the world. Many foods consumed today have high cholesterol content. Once the cholesterol reaches the small intestine it can be absorbed which results in an increase in serum cholesterol levels. The serum cholesterol is well-known to be deposited in various parts of the circulatory system, for example, in soft tissues.
The long-term accumulation or build-up of cholesterol deposits leads to atherosclerotic disease.
Field of the Invention This invention relates to plant stanol compositions and its derivatives for reduction of cholesterol absorption. More particularly, the invention provides compositions containing a phytostanol and/or a phytostanol ester and surfactants) that are useful for reducing cholesterol absorption. The invention also relates to methods of preparing such compositions for reducing cholesterol absorption.
Related Background Art Cholesterol, while an essential nutrient for humans, is well known to be a leading cause of death in the United States and most countries around the world. Many foods consumed today have high cholesterol content. Once the cholesterol reaches the small intestine it can be absorbed which results in an increase in serum cholesterol levels. The serum cholesterol is well-known to be deposited in various parts of the circulatory system, for example, in soft tissues.
The long-term accumulation or build-up of cholesterol deposits leads to atherosclerotic disease.
By reducing cholesterol content of food, as well as inhibiting the absorption of cholesterol, it has been possible to reduce serum levels of cholesterol. One of the areas that has been explored to control serum cholesterol levels is the use of dietary supplements, such as cholestyramine resin, probucol, colestipol HC1, nicotinic acid, mevinolin, pectin, guar gum, and oat bran. Another area, that has received considerable attention, has been the development of food additives that reduce the absorption of cholesterol in the small intestine. Prevention of the absorption of cholesterol results in lower levels of cholesterol in the blood and thus helps to prevent the formation of atherosclerotic plaques.
Plant sterols have been found to be particularly effective at reducing serum cholesterol levels. In particular, studies conducted employing beta-sitosterol were found to produce significant reductions (17~) in the amounts of cholesterol in the blood (Farquhar, J.W. et al., Circulation, 14, 77-82 (1956)). However, large doses of beta-sitosterol were required, 12-18 grams per day. This is a major impediment to the use of beta-sitosterol for cholesterol reduction. A related class of compounds, plant stanols (saturated plant sterols), have also been found to be effective for reducing cholesterol absorption. It has been postulated that plant stanols block cholesterol absorption by competing with cholesterol for bile acid micellerization. As a result of this competition between plant stanols and cholesterol, it is believed that plant stanols displace cholesterol from the micellar phase and thereby prevent its absorption in the small intestine.
Plant stanols and sterols have represented particularly attractive classes of compounds for use in lowering serum cholesterol levels, since they are natural components of vegetable fats and oils. Additionally, plant stanols and sterols are absorbed in very small quantities compared to the absorption of bile and dietary cholesterol. In fact, sitostanol is considered to be practically unabsorable, i.e., less than 5~. Although, plant sterols and stanols are attractive as cholesterol absorption inhibitors, they have proven to be difficult to formulate. A major factor in these difficulties has been the fact that plant stanols are virtually insoluble in water. Considerable efforts have been made to develop plant sterol or stanol preparations that can easily be formulated with consumer food products.
U.S. Patent No. 5,244,887 is directed to plant stanol food additives for reducing the absorption of cholesterol in the gastro-intestinal tract. The greatest effectiveness was obtained when the stanols were evenly distributed in finely divided form throughout the food product or beverage to which it is added. This was accomplished by dissolution of the stanols or by suspension of the stanols in an emulsion.
Solubilizing agents listed for the stanols include vegetable oil, monoglycerides, diglycerides, triglycerides, tocopherols, and the like and mixtures thereof. Suspensions or emulsions of stanols include water, alchohols, polyols, and other edible compounds. Dispersing agents may be used to aid in the formation of suspensions, such as lecithin, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, sodium lauryl sulfate, and the like.
The stanol food additives are used with cholesterol containing foods, such as meats, eggs and dairy products.
EP 0 897 671 discloses aqueous dispersions of high melting lipids, such as plant sterols, with non-sterol emulsifiers.
Emulsifiers used to disperse the high melting lipids include polyglycerol esters and tweens, especially polysorbate 60.
Mono- and diglycerides are also mentioned as suitable emulsifiers. The dispersions have reduced size on the order of 15 microns or lower. The dispersions are said to be useful in spreads and other food products. Additionally, the dispersions provide structure to the food products and their use can apparently permit minimization or elimination of saturated fats and trans fatty acids.
There is a continuing need for formulations which lower serum cholesterol levels by preventing or significantly reducing the absorption of cholesterol. Such formulations would desirably be able to be delivered in a variety of ways to individuals, e.g., as an additive to food products or as a pill for oral administration. Furthermore, in order for the formulations to be most effective in lowering cholesterol absorption, the formulation must reach the gastrointestinal tract so that they can be rapidly and efficiently solublized in the micellar phase thereby preventing the absorption of cholesterol. It has now been discovered that formulations comprising a plant stanol or a plant stanol ester and a surfactants) are effective at inhibiting the absorption of cholesterol.
SUMMARY OF THE INVENTION
Compositions for inhibiting the absorption of cholesterol are disclosed. The compositions comprise a plant stanol and/or a plant stanol ester and a surfactant(s). The surfactants) is selected from the group consisting of anionic, cationic, nonionic and zwitterionic surfactants.
Examples of plant stanols that may be employed include sitostanol, campestanol, 22, 23 dihydorbrassicastanol, and clionastanol. The compositions of the present invention provide an effective method of reducing cholesterol without any adverse side-effects.
The compositions of the present invention can be used as food additive compositions for reducing cholesterol absorption from foods. The food additive composition may be employed in small quantities making it convenient for use and also an inexpensive method to reduce cholesterol absorption. The food additive compositions of the present invention are storage-stable for extended periods of time.
The food additive compositions may be added before, during or after cooking with foods. The food additive compositions may be added to food products during production prior to sale to the consumer. Advantageously, the compositions of the present invention can be used in non-fat containing foods.
The present invention also contemplates various combinations of the foregoing surfactants) and a phytostanol and/or a phytostanol ester being administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the use of plant stanol and/or plant stanol ester compositions that inhibit the absorption of cholesterol. More particularly, the invention relates to the formation of water soluble/dispersible stanol and/or stanol°ester systems comprising a plant stanol and/or a plant stanol ester and anionic, cationic, nonionic, or zwitterionic surfactant systems, which reduce cholesterol absorption.
The terms "phytostanols" and "stanols" are used herein interchangeably. The term "stanols" as used herein refers to plant sterol derivatives in which all carbon-carbon bonds in the rings are saturated. The principal stanols of the present invention are those which are composed of 28 or 29 carbon atoms. Four major plant stanols are beta-sitostanol, campestanol, 22,23 dihydrobrassicastanol, and clionastanol.
The Lipids, Vol. 1, Deuel, H. J., Jr., Interscience Publishers, 1951, N.Y., pp. 348-361.
These four stanols have the following structure H
where R is CH3 for campestanol and its epimer, 22,23 dihydrobrassicastanol and where R is CzHs for sitostanol and its epimer, clionastanol. The C28 stanols campestanol and 22, 23 dihydrobrassicastanol differ only by their steric configuration at C24. The CZ9 stanols, likewise, differ only by the steric configuration at C24. Alternate nomenclature for clionastanol is (3 beta, 5 alpha, 24S)-Stigmast-San-3-ol; sitostanol is (3 beta, 5 alpha, 24R)-Stigmast-San-3-ol; campestanol is (3 beta, 5 alpha, 24R)-Ergost-5an-3-0l; 22, 23 dihydrobrassicastanol is (3 beta, 5 alpha, 24S)-Ergost-San-3-ol. It will also be appreciated that modifications of the plant stanols are also well within the scope of the present invention, for example, small side chains.
The terms "phytostanol ester" and "stanol esters" are used _g_ herein interchangeably. The term "stanol ester" as used herein refers to plant stanols that has been modified to form a plant stanol ester derivative. These derivatives are well known in the art and are described in U.S. Pat. Nos.
4,588,717, 5,270,041, and 5,958,913, International applications WO 98/06405, and WO 99/25362, European Application EP 911385, and H. Gylling et al., Journal of Lipid Research, 40, 593-600 (1999), the disclosures which are hereby incorporated by reference.
Stanols are found in small quantities in nature in many plants, e.g., wheat, rye, and corn. As a result, this is not a particularly good source of large quantities of stanols due to the large cost associated with extraction of sufficient quantities of stanols. A more cost effective method to obtain large quantities of stanols is by hydrogenation of the much more abundant plant sterols. Many hydrogenation methods for plant sterols are well-known by those of ordinary skill in the art. For example, plant sterols can be converted into stanols by hydrogenation techniques that employ Pd/C catalyst in organic solvents (Augustine, R.L. et al., Org. Prep. and Proc. 1: 107-109, (1969)).
A larger number of inexpensive sources of plant sterols are known. These include, vegetable oils, vegetable oil sludge, vegetable oil distillates, and other plant oil sources such as tall oils. For example, a preparation of sterols from vegetable oil sludge by using solvents such as methanol is taught in U.S. Pat. No. 4,420,427. Sterols isolated from _9_ plant sources are usually mixtures of several different sterols, hydrogenation leads to a mixture the corresponding stanols. Sterols, which differ only by the degree of unsaturation in the carbon bonds of the ring or side chains, upon hydrogenation usually produce stanols which differ only in epimeric centers such as the Cz4 carbon.
One preferred plant stanol, sitostanol, may be obtained by hydrogenation of sitosterol. Sitosterol may be obtained from cold pressed wheat germ oil, soy extract, or rice extract. (It will be appreciated that natural sitosterol contains about 40~ alpha-sitosterol and about 60~ beta-sitosterol. Both the alpha and beta forms of sitosterol may be used to form sitostanol for use in the present invention.) Particularly preferred stanol comprises a minimum of 63 weight percent sitostanol, a maximum of 35 weight percent campestanol and a minimum of 93 weight percent of sitostanol and campestanol.
It should also be noted that hydrogenation of plant sterols may leave some amounts of unreacted sterols. Although, the hydrogenation results in a majority of stanol production.
For the purposes of the present invention, it is acceptable to have small residual amounts of unreacted sterols, generally less than about 10~. It will be readily apparent to those of ordinary skill in the art that amount of residual sterol present may be substantially reduced (<1.5~) depending on the solvents and reaction conditions employed.
However, if it is desired to have a stanol free of unreacted sterols, then a pure sterol preparation may be employed.
The surfactants to be employed according to the invention can be anionic, cationic, nonionic, zwitterionic and mixtures thereof. Suitable anionic surfactants include AOT, also known as sodium dioctylsulfosuccinate or sodium docusate, ammoniated glycyrrhizin, and sodium stearoyl lactylate. Nonionic surfactants include, polyoxyethylene castor oil (cremophor EL polyoxyl 35 castor oil), polyethylene glycol "PEG" (low molecular weight 1000 to 4000), diacetyl lactic acid of esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sorbitan esters of fatty acids, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E
TPGS (d-alpha tocopheryl poyethylene glycol 1000 succinate), fatty alcohols and sucrose fatty acid esters, such as sucrose stearate, sucrose distearate, sucrose palmitate.
Preferred fatty alcohols include but are not limited to the following, 1-decanol ( CH3 ( CHZ ) $CHZOH ) also known as n-decyl alcohol, 1-dodecanol ( CH3 ( CHZ ) loCH20H ) also known as dodecyl or lauryl alcohol, 1-tetradecanol ( CH3 ( CHZ ) l2CHzOH ) also known as myristyl alcohol, 1-hexadecanol ( CH3 ( CHz ) ~4CHZOH ) also known as cetyl or palmityl alcohol, 1-octadecanol ( CH3 ( CHZ ) 16CHZOH ) also known as stearyl alcohol, 9-octadecen-1-0l ( CH3 ( CHZ ) NCH=CH ( CHZ ) ~CHZOH ) also known as oleyl alcohol , 1-eicosanol ( CH3 ( CHZ ) lgCH20H ) also known as arachidyl alcohol, 1-docosanol ( CH3 ( CHZ ) ZoCH20H ) also known as behenyl alcohol, 1-hexacosanol ( CH3 ( CHZ ) zaCHzOH ) , 1-octacosanol ( CH3 ( CHZ ) ZsCHzOH ) also know as octacosyl alcohol (wheat leaf wax), 1-triacontanol ( CH3 ( CHZ ) ZBCHZOH ) also known as melissyl alcohol (beeswax as stearate). A particularly preferred fatty alcohol is 1-octadecanol.
Zwitterionic surfactants include, hydroxylated lecithin and the like.
Other anionic surfactants such as sodium stearate, sodium palmitate, sodium laurate, sodium myristate, sodium linoleate, and potassium oleate may also be employed.
Additional nonionic surfactants that may be included in the compositions of the present invention include polyglycerol esters and tweens, polysorbate 20 (tween 20), polysorbate 40 (tween 40), polysorbate 60 (tween 60), polysorbate 80 (tween 80), polysorbate 85 (tween 85), fatty acids such as oleic acid ( C1~H33COOH ) , stearic acid ( C1,H36COOH ) , and palmitic acid ( C15H31COOH ) , triglycerides CH3 ( CHz ) 6COOH and CH3(CHZ)BCOOH and mixtures thereof (e. g., MCT oil).
Naturally occurring polymers such as guar gum, karaya gum, gum arabic, carrageenan, xanthan gum, dextran, maltodextrin, chondroitin sulfate, polyglycerol esters of fatty acids commercially known as Polyaldo, succinoglucan and hyaluronic acid may also be employed in the compositions of the present invention. Synthetic polymers such as polyvinyl alcohol), polyvinyl pyrrolidone), hydroxypropyl methyl cellulose, and sodium carboxymethyl cellulose may also be employed in the compositions of the present invention.
Other fatty acids, that may be employed in the present invention, include caprylic, capric, lauric, myristic, myristoleic, palmitoleic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachidic, arachidonic, behenic and erucic acid. The fatty acids of the present invention can be derived from naturally occurring or synthetic fatty acids; they can be saturated or unsaturated, including positional and geometric isomers, depending on the desired physical properties, for example liquid or solid.
In one preferred embodiment the composition of the present invention comprises a mixture of a phytostanol and/or a phytostanol ester and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof. The composition of the present invention may further comprise a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
One preferred embodiment of the present invention comprises a mixture of a phytostanol and/or a phytostanol ester and fatty acid alcohol, preferably, octadecanol. Another preferred embodiment of the present invention comprises a mixture a phytostanol and/or a phytostanol ester, Tween 60 and PEG. Other preferred embodiments include a phytostanol and/or a phytostanol ester, fatty acid alcohol and sucrose fatty acid ester, such as Crodesta.
One preferred embodiment of the present invention provides a method of reducing cholesterol absorption in humans which comprises orally administering an effective amount of a composition of the present invention. The invention also provides for a method for reducing serum cholesterol levels comprising administering a mixture of a phytostanol and/or a phytostanol ester and a surfactant(s).
In another embodiment of the present invention, emulsifiers may be used in the formulation of dispersible stanol and/or stanol ester systems. Preferred emulsifiers include a variety of phospholipids, phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), N-acylphosphatidyl ethanolamine (NAPE), phosphatidyl serine (PS), phosphatidyl inositol (PI), phosphatidyl glycerol (PG), diphosphatidyl glycerol (DPG), phosphatidic acid (PA) and plasmalogen.
These and other phospholipids are described, for example, in Szuhaj and List (eds.), Lecithins, American Oil Chemists Society (1985) ("Szuhaj and List"), incorporated herein in its entirety by reference.
The phospholipids may be used individually or in various combinations, and may be obtained from "natural" sources (e.g., soybean lecithin) or from chemical synthesis. The phospholipids may be in the form of relatively unpurified mixtures of phospholipids and other constituents (e. g., crude commercial lecithins obtained from the refining of soybean oil and other vegetable oils such as sunflower and canola), or may be purified to various degrees. In addition, phospholipids including those found in crude soybean lecithins or other crude commercial lecithins may be chemically modified. Lecithins, other phospholipid preparations, or individual phospholipids purified from natural sources or obtained by chemical synthesis, contain one or more functional groups susceptible to chemical modification, e.g., carbon-carbon double bonds, esters, phosphonate esters, amines and hydroxyl groups. Chemical modification of phospholipids can be compatible with the present methods. Thus, phospholipids that have been acetylated, hydroxylated, hydrolyzed (e. g., to produce lysophospholipids), hydrogenated, halogenated, phosphorylated, sulfated epoxidated, ethoxylated, or otherwise modified are potentially useful in the present methods and are included within the meaning of the term "phospholipid" as used herein. Various natural and synthetic phospholipids, including various types of lecithins, may be obtained commercially, for example Ultralec from ADM Corp., and other lecithins may be obtained from CALBIOCHEM~, La Jolla, Calif., USA and from SIGMA~
Chemical Company, St. Louis, Mo., USA.
In common usage, the term "lecithin" refers to the entire phospholipid fraction obtained from natural sources such as soybean, cotton seed, corn, wheat germ, oat, barley, sunflower, rapeseed, canola, linseed, peanut, palm kernel, egg yolk, milk and brain. Generally these fractions include a mixture of polar and neutral lipids with a polar lipid content (as defined by insolubility in acetone) of at least 50~. The art has also used the term "lecithin" as the common name for phosphatidyl choline. The term "lecithin"as used herein refers to the first usage, i.e., the entire phospholipid fraction obtained from selected vegetable oils or other appropriate sources. See, Chapter 2 of Szuhaj and List. It is to be noted, however, that phosphatidyl choline is an appropriate phospholipid for use in the present methods, either alone or in combination with other phospholipids.
Commercial soybean lecithin, a preferred source of phospholipids, is obtained from the refining of soybean oil.
Crude soybean oil generally contains about 1.0 to 3.0 weight percent phospholipids. When the crude oil is refined, the first step generally is to remove the phospholipids. This step, often called "degumming," is accomplished by first adding water to the crude oil. The water hydrates the phospholipids and makes them less soluble in the oil. The denser phospholipids and water are then separated from the less-dense oil, typically by centrifugation. Removal of the water from the dense phase results in a product having approximately equal amounts of phosphatidyl choline, phosphatidyl ethanolamine, and inositol phosphatides.
Partially refined soybean oil is commonly added back to produce a liquid product that is flowable at room temperature (sometimes called "fluidized lecithin").
Commercial fluid soybean lecithin contains about 50 to about 65 weight percent phospholipids and a small amount (generally less than about 5 weight percent) of various carbohydrates, mineral salts, protein materials, free fatty acids, sterols, and water. The remainder of commercial soybean lecithin is soybean oil.
Various lecithin powders enriched for phospholipid content are available commercially and may also be used in the present methods. Such lecithin powders are also within the scope of the term "lecithin" as used herein. The powders are typically derived by fractionation, for example acetone fractionation, of crude lecithins such as commercial soybean lecithin, and may contain from about 60~ to over 95~
phospholipid.
Another commercial source of phospholipids is the class of products, resulting from modification of soybean lecithin to improve its hydrophilic properties. Various approaches have been taken to effect these modifications. For example, soybean lecithin may be chemically or ezymatically modified, e.g., via reaction with malefic anhydride. Certain components may be removed from commercial soybean lecithin.
Alternatively, another approach is to add various components, for example nonionic emulsifiers, to the commercial soybean lecithin. Such emulsifiers include, without limitation, polyoxyalkylene monoglyceride, polyoxyalkylene diglycerides, and the polyoxyethylene derivatives of partial fatty acid esters. These modified lecithins are also included in the term "lecithin" as used herein.
Hydroxylated lecithin is a preferred embodiment of the phospholipids used in the invention. Hydroxylated lecithin is prepared by hydroxylating the double bonds in the fatty acids attached to the phospholipids and glycolipids of lecithin, which can be carried out by reaction with hydrogen peroxide and a weak acid such as lactic acid. Although not wishing to be bound by theory, it is believed that hydroxylation is not specific and can occur at any double bond within any of the lipids. The degree of hydroxylation is typically about 10$ but can be varied by methods known to those of ordinary skill in the art.
The compositions of the present invention are preferably formed into a fine dispersion using melt processing. One particular preferred method of melt processing comprises dry-mixing a phytostanol and/or a phytostanol ester and a surfactants) together with a stirring device such as a mechanical stirrer, shear mixer, vibrational mixer or sonicator. The mixture is then heated to a temperature sufficient to melt same, but not so high as to degrade the phytostanol, phytostanol ester or surfactant(s). The resulting mixture is then rapidly cooled, e.g., liquid nitrogen, to form a salt like material. While not wishing to be limited by theory, it is believed that the step of melt blending the phytostanol and/or phytostanol ester and surfactants) prior to rapid cooling facilitates the formation of a composition that is in a finely dispersed state that is able to reach the small intestine thereby being able to inhibit the absorption of cholesterol.
An alternative variation on the melt processing described above comprises the addition of a surfactants) to a phytostanol and/or phytostanol ester melt. This may be desirable in cases where the surfactants) is thermally unstable and would not survive prolonged heating at high temperatures, i.e., thus the residence time for the surfactants) is reduced by its later addition to phytostanol melt. Once the surfactants) has been added to the melt, the mixture can be treated in a fashion similar to that described previously.
A further alternative procedure to melt blending for forming the compositions of the present invention is high pressure melting. This procedure is also desirable for blending heat sensitive surfactants) and phytostanol and/or phytostanol esters. It has been discovered that by using a mixing or compression means allowing for increasing the pressure on the ingredients, the surfactants) phytostanol and/or phytostanol esters will melt blend at ambient temperatures.
Homogenous mixtures of heat sensitive surfactants) and phytostanol and/or phytostanol esters can therefore be formed while avoiding temperatures at which thermal decomposition of ingredients will occur.
One embodiment of high pressure melting is roller compaction, where the surfactants) and phytostanol and/or phytostanol ester are mixed together as described previously. The mixture is then compressed together using a roller such that the pressure exerted on the mixture is high enough to result in the flow of the ingredients and surface sintering of the mixture results.
An additional embodiment of high pressure melting is extrusion. For example, in an extrusion process, a loosely packed powder mixture of surfactants) and phytostanol and/or phytostanol ester, is propelled continuously along a screw through regions of high pressure and controlled temperature. Shear forces from the screw melt and mix the material into a continuous stream of molten material, which is then forced through a die.
The mixture resulting from the high pressure melting process is typically a soft, pliable solid material that can be further processed by cooling to solidify followed by breaking into chips or milling to form a uniform powder for use in the formation of products as described herein.
Mixtures of a phytostanol and/or a phytostanol ester and surfactants) may also be processed using solution processing or steric stabilization. Use of solution processing is particularly effective for use with surfactants) that are thermally stable. The phytostanol and/or phytostanol ester and surfactants) are generally dry mixed together, although this is not always necessary, the resulting solid mixture is then dissolved in an organic solvent, such as methylene chloride. The solvent is then removed to provide an amorphous/dispersible solid form.
Steric stabilization provides an effective method to form a dispersible solid form of a phytostanol and/or phytostanol ester and surfactant(s). A fine dispersion of a phytostanol and/or phytostanol ester is added to water containing the surfactant(s). The surfactants) in the water help to keep the stanol(s) in suspension. Once a finely divided suspension has formed the water is evaporated off leaving a more readily dispersible solid form.
Preferred embodiments of the present invention include a mixture of from about 10 to about 99.99 weight percent of a phytostanol and/or phytostanol ester and from about 0.01 to about 90 weight percent of a surfactant(s), preferably from about 40 to about 95 weight percent of a phytostanol and/or phytostanol ester and from about 5 to about 60 weight percent of a surfactant(s), and more preferably about 95 weight percent of a phytostanol and/or phytostanol ester and about 5 percent by weight percent of a surfactant(s).
In one preferred embodiment of the present invention, the compositions of the present invention comprise a phytostanol and/or phytostanol ester and at least two surfactants. Such a mixture comprises from about 10 to about 99.99 weight percent of a phytostanol and/or phytostanol ester and the sum of the at least two surfactants is from about 0.01 to about 90 weight percent, preferably such a mixture comprises from about 40 to about 95 weight percent of a phytostanol and/or phytostanol ester and the sum of at least two surfactants is from about 5 to about 60 weight percent, and more preferably about 95 weight percent of a phytostanol and/or phytostanol ester and the sum of at least two surfactants is about 5 weight percent.
Desirable characteristics of food additive compositions for reducing cholesterol absorption include absence of side effects, efficacy without absorption of the compound, stability at cooking temperatures, stability in storage and in oxidizing environments, low cost, availability, and small dose requirements.
The compositions of the present invention may be orally administered in a variety of forms: uncoated tablets, coated tablets such as film, sugar or gelatin coated, chewable tablets, swallowable tablets (capsules), effervescent tablets, immediate release tablets, sustained (controlled or modified) release tablets; soft gelatin capsules either liquid (non-aqueous) or paste (slurry); hard gelatin capsules in powder (granulation), bead, tablet, liquid, semi-solid, sprinkle (immediate or controlled release) forms; oral liquids such as aqueous, emulsions or suspension; sachets (packages) in powder, granule or sprinkle (immediate or controlled release) forms. Other forms for administering the compositions of the present invention include syrup, fruit beverages, or fruit gelatines.
Although the composition of the invention may be used in various embodiments it may be said, one preferred embodiment is when the compositions of the present invention are evenly distributed in finely divided form throughout the food product or beverage to which it is added. The compositions of the present invention may be added to food products or beverages prior to purchase by the consumer for consumption.
Alternatively, the compositions of the present invention may be purchased in bulk form or individually wrapped packages, e.g., 8 oz. servings. A serving from the bulk form, e.g., 8 oz., or the contents of a package may be added to a glass of cold or hot water or other beverage, stirred to dissolve the contents, prior to consumption. Typical beverages include the following, instant ice tea in Orange Pekoe, English Breakfast, Passion Fruit and Hisbiscus Flavors, powdered soft drinks such as Crystal Light and Contry Time Lemonade, Instant Iced Coffee in flavors such as Mocchacchino, Hazelnut, French Vanilla, and Hot Chocolate and Fruit Smoothies.
The compositions of the present invention may also be included in mini-sweets. The mini-sweets will typically be consumed after any and all meals of each day. The mini-sweets will typically contain between 25 and 60 calories and 1 to 3 grams of fat. Mini-sweets include the following varieties: chocolate chews; caramel chews; hard candies such as cinnamon, butterscotch, coffee and fruit flavors;
chocolate truffles such as hard dark chocolate on the outside filled with hazelnut creme, Irish creme or cappucinno creme; brownie bites; cookie chews in peanut butter, chocolate chip or ginger snaps; granola/nutrition bar miniatures such as chocolate covered oat and peanut butter; chewy breath mints; mint meltaways; and mini-pudding. Mini-sweets may be prepared in individually wrapped packages or in larger containers for multiple uses.
The method by which the novel food additive composition, i.e., the stanol and/or stanol ester and surfactant(s), is used to reduce cholesterol absorption from foods and beverages includes the step of commingling the food additive composition with foods and beverages, mixing until uniformly blended.
In a preferred method of commingling the indicated food additive with foods and beverages which contain cholesterol, the food additive is added such that the amount of stanols in the food additive is in the ratio of about 1:1 by weight to the cholesterol contained in the foods and beverages.
Thus, for a food additive composition which comprises 25$
stanols and a food which contains about 0.1~ cholesterol (such as hamburger), the ratio of food additive to food product is about 1:250 by weight.
The food additive composition of the invention can be commingled with foods by a step selected from the group of infusion, injection, mixing, kneading, blending, immersion, spraying, surface application (for example, brushing and basting), cooking in oils which contain the food additive-invention, and combinations thereof. Preferred steps for commingling the food additive-invention with ground meat are kneading and mixing; for meat pieces such as steaks, chicken breasts, and chopped, diced or sliced meat, the preferred steps are injection, infusion, spraying, immersion, and surface applications such as basting and marinating. Two preferred steps for commingling the food additive-invention with beverages are mixing and blending.
The compositions of the present invention will be used as food additives to foods such as meats, eggs and dairy products. Generally, when used as food additives, the compositions of the present invention will not contribute substantially to the taste of the food product.
Accordingly, the compositions of the present invention can be used in food products without compromising the food products taste and flavor.
The compositions of the present invention may also be formulated into fine particles which may be sprinkled on to other food products, i.e., dairy products such as ice cream or candy.
The compositions of the invention may be administered to any animal. Foremost among such animals are mammals, e.g., humans, although the invention is not intended to be so limited. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
The compositions of the present invention may be administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations. The term unit dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage to animals, each unit containing a predetermined quantity of active material, i.e., phytostanol and/or phytostanol ester, in association with a surfactants) and a carrier. The quantity of active material is that calculated to produce the desired therapeutic effect upon administration of one or more of such units. Of course, it is understood that the exact treatment level will depend upon the case history of the animal, e.g., human being, that is treated. The precise treatment level can be determined by one of ordinary skill in the art without undue experimentation.
The require dosage of the phytostanol and/or phytostanol ester will vary with the severity of the condition and the duration of the treatment. Unit dosages can range from about 0.01 mg/kg to about 500 mg/kg (the unit designated "mg/kg" as used herein refers to mg of phytostanol and/or phytostanol ester per kilogram of body weight), preferably from about 0.1 mg/kg to about 125 mg/kg with up to six doses daily, preferably four dosages daily. Most preferably, the doses are administered at meal times. The dosages may be administered orally in any suitable unit dosage form such as pills, tablets, and capsules. Preferred are capsules made from gelatin.
As used herein, the term "carrier" denotes a solid or liquid filler, diluent, or encapsulating substance. Some examples of the substances that can act as carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc;
stearic acid; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and of the broma; polyols such as propylene glycol, glcerin, sorbitol, mannitol, and polyethylene glycol; agar, alginic acid; pyrogen-free water; isotonic saline; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in preparation of formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, and preservatives can also be present.
Dye stuffs or pigments may be added to the tablets, for example, for identification or in order to characterize combinations of active doses Other preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
Powders are prepared by comminuting the compositions of the present invention to a suitable fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch.
Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
Capsules are made by preparing a powder mixture as described above and filling formed gelatin sheaths. A lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation; a glidant such as colloidal silica may be added to improve flow properties; a disintegrating or solubilizing agent may be added improve the availability of the medicament when the capsule is ingested.
Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compositions of the present invention, suitable comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules.
The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The medicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps. A protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dye stuffs or pigments may be added to the tablets, for example, for identification or in order to characterize combinations of active doses. In tablet form the carrier comprises from about 0.1$ to 99~ by weight of the total composition.
This invention will be better understood from the Examples which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention and no limitation of the invention is implied.
Soy sitostanol (AC Humko, NF00114) (1g) was physically mixed with an equal weight of sodium dioctylsulfosuccinate (Aldrich Chemicals). The blend was melted at 170°C to form a clear solution. The clear solution was rapidly cooled by pouring it into liquid nitrogen. A crystalline transparent salt was obtained. The salt (2g) was added to water (8g) to give a milky-white emulsion with no visible particles. The solubility of the crystalline was found to be 1200 micrograms per ml using the dissolution assay described below. (Maximum solubility of cryground beta-sitostanol in the dissolution assay was found to be 300 micrograms per ml.) Dissolution Assay A stock dissolution solution (5X) was prepared comprising taurocholic acid, Na2+ (500 mM, Sigma, cat# T4009), 2-monoolein (10 mM, Nu-Check Prep, cat# M-239), oleic acid, free (10 mM, Sigma cat# 01008) in cholorform:MeOH (1:1). A
buffer solution was prepared comprising O.O1M sodium phosphate buffer with 3 mM sodium azide, pH 7.4.
In order to prepare the dissolution solution for use in the dissolution assay 1 ml of the 5X stock dissolution solution in a 20 ml vial was dried down under an NZ stream at 50°C.
The dried down dissolution solution was then redried twice from 2 ml ethyl ether with vortexing of the vial following each addition. Excess ether was then driven off by drying the vial for 1 hour at 100°C in an oven.
The vial with the dried down dissolution solution was rehydrated with 5 ml of the sodium phosphate buffer.
Nitrogen was bubbled through the solution for 5 minutes to ensure complete removal of ether. The final concentrations of the dissolution constituents were taurocholic acid (100 mM), 2-monoolein (2 mM), oleic acid ~2 mM) in sodium phosphate (0.01 M, pH 7.4) with 3 mM NaN3.
In order to determine the solubility of the blend of the present Example, a sample of the blend having an equivalent of 100 mg sitostanol was added to the vial with the 5 ml of the rehydrated dissolution solution. The contents of the vial were gently swirled and then placed in rotating incubator. A 100 mg cholesterol sample was prepared for assaying in the same manner as the blend of the present Example, as well as a 100 mg sample of cryoground stanol.
At 4 hours a 1.0 ml aliquot was removed from each vial. The aliquots were immediately filtered through a 0.2 arm syringe filter.
Using a Cholesterol CII Enzymatic Kit (Wako Pure Chemical Industries, Ltd.) the amount of stanol dissolved in the filtered dissolution solution was determined according to the following protocol. Note that the concentration of stanol is given as the amount of unesterified stanol.
1. A 2X color reagent was prepared by adding only one-half the recommended buffer solution to the supplied lyophilized color reagent.
2. A 0.2 mg/ml sitostanol standard was prepared by aliquoting sitostanol from a 1:1 CHC13/MEOH stock and adding triton-X 100 for a final rehydrated concentration of 2.0~
Triton, 0.2 mg/ml sitostanol. This solution was vortexed and dried down under a NZ stream at 50°C, followed by redrying twice from ethyl ether. The sample was rehydrated in of 0.01 M sodium phosphate buffer with 3 mM NaN3, pH 7.4.
The mixture was then vortexed.
4. A 96 well plate was setup. The first two columns were used for the standard. Each sample was run in quadruplicate.
5. Samples for a standard curve were formed by adding water to the well first followed by the standard according to the proportions outlined in the table below:
Water Sitostanol Sitostanol (ml) Standard (mg) (ml) 97.5 2.5 0.5 6. Samples (5 microliter) were added to wells containing water so that the final volume was 100 ml.
Plant sterols have been found to be particularly effective at reducing serum cholesterol levels. In particular, studies conducted employing beta-sitosterol were found to produce significant reductions (17~) in the amounts of cholesterol in the blood (Farquhar, J.W. et al., Circulation, 14, 77-82 (1956)). However, large doses of beta-sitosterol were required, 12-18 grams per day. This is a major impediment to the use of beta-sitosterol for cholesterol reduction. A related class of compounds, plant stanols (saturated plant sterols), have also been found to be effective for reducing cholesterol absorption. It has been postulated that plant stanols block cholesterol absorption by competing with cholesterol for bile acid micellerization. As a result of this competition between plant stanols and cholesterol, it is believed that plant stanols displace cholesterol from the micellar phase and thereby prevent its absorption in the small intestine.
Plant stanols and sterols have represented particularly attractive classes of compounds for use in lowering serum cholesterol levels, since they are natural components of vegetable fats and oils. Additionally, plant stanols and sterols are absorbed in very small quantities compared to the absorption of bile and dietary cholesterol. In fact, sitostanol is considered to be practically unabsorable, i.e., less than 5~. Although, plant sterols and stanols are attractive as cholesterol absorption inhibitors, they have proven to be difficult to formulate. A major factor in these difficulties has been the fact that plant stanols are virtually insoluble in water. Considerable efforts have been made to develop plant sterol or stanol preparations that can easily be formulated with consumer food products.
U.S. Patent No. 5,244,887 is directed to plant stanol food additives for reducing the absorption of cholesterol in the gastro-intestinal tract. The greatest effectiveness was obtained when the stanols were evenly distributed in finely divided form throughout the food product or beverage to which it is added. This was accomplished by dissolution of the stanols or by suspension of the stanols in an emulsion.
Solubilizing agents listed for the stanols include vegetable oil, monoglycerides, diglycerides, triglycerides, tocopherols, and the like and mixtures thereof. Suspensions or emulsions of stanols include water, alchohols, polyols, and other edible compounds. Dispersing agents may be used to aid in the formation of suspensions, such as lecithin, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, sodium lauryl sulfate, and the like.
The stanol food additives are used with cholesterol containing foods, such as meats, eggs and dairy products.
EP 0 897 671 discloses aqueous dispersions of high melting lipids, such as plant sterols, with non-sterol emulsifiers.
Emulsifiers used to disperse the high melting lipids include polyglycerol esters and tweens, especially polysorbate 60.
Mono- and diglycerides are also mentioned as suitable emulsifiers. The dispersions have reduced size on the order of 15 microns or lower. The dispersions are said to be useful in spreads and other food products. Additionally, the dispersions provide structure to the food products and their use can apparently permit minimization or elimination of saturated fats and trans fatty acids.
There is a continuing need for formulations which lower serum cholesterol levels by preventing or significantly reducing the absorption of cholesterol. Such formulations would desirably be able to be delivered in a variety of ways to individuals, e.g., as an additive to food products or as a pill for oral administration. Furthermore, in order for the formulations to be most effective in lowering cholesterol absorption, the formulation must reach the gastrointestinal tract so that they can be rapidly and efficiently solublized in the micellar phase thereby preventing the absorption of cholesterol. It has now been discovered that formulations comprising a plant stanol or a plant stanol ester and a surfactants) are effective at inhibiting the absorption of cholesterol.
SUMMARY OF THE INVENTION
Compositions for inhibiting the absorption of cholesterol are disclosed. The compositions comprise a plant stanol and/or a plant stanol ester and a surfactant(s). The surfactants) is selected from the group consisting of anionic, cationic, nonionic and zwitterionic surfactants.
Examples of plant stanols that may be employed include sitostanol, campestanol, 22, 23 dihydorbrassicastanol, and clionastanol. The compositions of the present invention provide an effective method of reducing cholesterol without any adverse side-effects.
The compositions of the present invention can be used as food additive compositions for reducing cholesterol absorption from foods. The food additive composition may be employed in small quantities making it convenient for use and also an inexpensive method to reduce cholesterol absorption. The food additive compositions of the present invention are storage-stable for extended periods of time.
The food additive compositions may be added before, during or after cooking with foods. The food additive compositions may be added to food products during production prior to sale to the consumer. Advantageously, the compositions of the present invention can be used in non-fat containing foods.
The present invention also contemplates various combinations of the foregoing surfactants) and a phytostanol and/or a phytostanol ester being administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the use of plant stanol and/or plant stanol ester compositions that inhibit the absorption of cholesterol. More particularly, the invention relates to the formation of water soluble/dispersible stanol and/or stanol°ester systems comprising a plant stanol and/or a plant stanol ester and anionic, cationic, nonionic, or zwitterionic surfactant systems, which reduce cholesterol absorption.
The terms "phytostanols" and "stanols" are used herein interchangeably. The term "stanols" as used herein refers to plant sterol derivatives in which all carbon-carbon bonds in the rings are saturated. The principal stanols of the present invention are those which are composed of 28 or 29 carbon atoms. Four major plant stanols are beta-sitostanol, campestanol, 22,23 dihydrobrassicastanol, and clionastanol.
The Lipids, Vol. 1, Deuel, H. J., Jr., Interscience Publishers, 1951, N.Y., pp. 348-361.
These four stanols have the following structure H
where R is CH3 for campestanol and its epimer, 22,23 dihydrobrassicastanol and where R is CzHs for sitostanol and its epimer, clionastanol. The C28 stanols campestanol and 22, 23 dihydrobrassicastanol differ only by their steric configuration at C24. The CZ9 stanols, likewise, differ only by the steric configuration at C24. Alternate nomenclature for clionastanol is (3 beta, 5 alpha, 24S)-Stigmast-San-3-ol; sitostanol is (3 beta, 5 alpha, 24R)-Stigmast-San-3-ol; campestanol is (3 beta, 5 alpha, 24R)-Ergost-5an-3-0l; 22, 23 dihydrobrassicastanol is (3 beta, 5 alpha, 24S)-Ergost-San-3-ol. It will also be appreciated that modifications of the plant stanols are also well within the scope of the present invention, for example, small side chains.
The terms "phytostanol ester" and "stanol esters" are used _g_ herein interchangeably. The term "stanol ester" as used herein refers to plant stanols that has been modified to form a plant stanol ester derivative. These derivatives are well known in the art and are described in U.S. Pat. Nos.
4,588,717, 5,270,041, and 5,958,913, International applications WO 98/06405, and WO 99/25362, European Application EP 911385, and H. Gylling et al., Journal of Lipid Research, 40, 593-600 (1999), the disclosures which are hereby incorporated by reference.
Stanols are found in small quantities in nature in many plants, e.g., wheat, rye, and corn. As a result, this is not a particularly good source of large quantities of stanols due to the large cost associated with extraction of sufficient quantities of stanols. A more cost effective method to obtain large quantities of stanols is by hydrogenation of the much more abundant plant sterols. Many hydrogenation methods for plant sterols are well-known by those of ordinary skill in the art. For example, plant sterols can be converted into stanols by hydrogenation techniques that employ Pd/C catalyst in organic solvents (Augustine, R.L. et al., Org. Prep. and Proc. 1: 107-109, (1969)).
A larger number of inexpensive sources of plant sterols are known. These include, vegetable oils, vegetable oil sludge, vegetable oil distillates, and other plant oil sources such as tall oils. For example, a preparation of sterols from vegetable oil sludge by using solvents such as methanol is taught in U.S. Pat. No. 4,420,427. Sterols isolated from _9_ plant sources are usually mixtures of several different sterols, hydrogenation leads to a mixture the corresponding stanols. Sterols, which differ only by the degree of unsaturation in the carbon bonds of the ring or side chains, upon hydrogenation usually produce stanols which differ only in epimeric centers such as the Cz4 carbon.
One preferred plant stanol, sitostanol, may be obtained by hydrogenation of sitosterol. Sitosterol may be obtained from cold pressed wheat germ oil, soy extract, or rice extract. (It will be appreciated that natural sitosterol contains about 40~ alpha-sitosterol and about 60~ beta-sitosterol. Both the alpha and beta forms of sitosterol may be used to form sitostanol for use in the present invention.) Particularly preferred stanol comprises a minimum of 63 weight percent sitostanol, a maximum of 35 weight percent campestanol and a minimum of 93 weight percent of sitostanol and campestanol.
It should also be noted that hydrogenation of plant sterols may leave some amounts of unreacted sterols. Although, the hydrogenation results in a majority of stanol production.
For the purposes of the present invention, it is acceptable to have small residual amounts of unreacted sterols, generally less than about 10~. It will be readily apparent to those of ordinary skill in the art that amount of residual sterol present may be substantially reduced (<1.5~) depending on the solvents and reaction conditions employed.
However, if it is desired to have a stanol free of unreacted sterols, then a pure sterol preparation may be employed.
The surfactants to be employed according to the invention can be anionic, cationic, nonionic, zwitterionic and mixtures thereof. Suitable anionic surfactants include AOT, also known as sodium dioctylsulfosuccinate or sodium docusate, ammoniated glycyrrhizin, and sodium stearoyl lactylate. Nonionic surfactants include, polyoxyethylene castor oil (cremophor EL polyoxyl 35 castor oil), polyethylene glycol "PEG" (low molecular weight 1000 to 4000), diacetyl lactic acid of esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sorbitan esters of fatty acids, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E
TPGS (d-alpha tocopheryl poyethylene glycol 1000 succinate), fatty alcohols and sucrose fatty acid esters, such as sucrose stearate, sucrose distearate, sucrose palmitate.
Preferred fatty alcohols include but are not limited to the following, 1-decanol ( CH3 ( CHZ ) $CHZOH ) also known as n-decyl alcohol, 1-dodecanol ( CH3 ( CHZ ) loCH20H ) also known as dodecyl or lauryl alcohol, 1-tetradecanol ( CH3 ( CHZ ) l2CHzOH ) also known as myristyl alcohol, 1-hexadecanol ( CH3 ( CHz ) ~4CHZOH ) also known as cetyl or palmityl alcohol, 1-octadecanol ( CH3 ( CHZ ) 16CHZOH ) also known as stearyl alcohol, 9-octadecen-1-0l ( CH3 ( CHZ ) NCH=CH ( CHZ ) ~CHZOH ) also known as oleyl alcohol , 1-eicosanol ( CH3 ( CHZ ) lgCH20H ) also known as arachidyl alcohol, 1-docosanol ( CH3 ( CHZ ) ZoCH20H ) also known as behenyl alcohol, 1-hexacosanol ( CH3 ( CHZ ) zaCHzOH ) , 1-octacosanol ( CH3 ( CHZ ) ZsCHzOH ) also know as octacosyl alcohol (wheat leaf wax), 1-triacontanol ( CH3 ( CHZ ) ZBCHZOH ) also known as melissyl alcohol (beeswax as stearate). A particularly preferred fatty alcohol is 1-octadecanol.
Zwitterionic surfactants include, hydroxylated lecithin and the like.
Other anionic surfactants such as sodium stearate, sodium palmitate, sodium laurate, sodium myristate, sodium linoleate, and potassium oleate may also be employed.
Additional nonionic surfactants that may be included in the compositions of the present invention include polyglycerol esters and tweens, polysorbate 20 (tween 20), polysorbate 40 (tween 40), polysorbate 60 (tween 60), polysorbate 80 (tween 80), polysorbate 85 (tween 85), fatty acids such as oleic acid ( C1~H33COOH ) , stearic acid ( C1,H36COOH ) , and palmitic acid ( C15H31COOH ) , triglycerides CH3 ( CHz ) 6COOH and CH3(CHZ)BCOOH and mixtures thereof (e. g., MCT oil).
Naturally occurring polymers such as guar gum, karaya gum, gum arabic, carrageenan, xanthan gum, dextran, maltodextrin, chondroitin sulfate, polyglycerol esters of fatty acids commercially known as Polyaldo, succinoglucan and hyaluronic acid may also be employed in the compositions of the present invention. Synthetic polymers such as polyvinyl alcohol), polyvinyl pyrrolidone), hydroxypropyl methyl cellulose, and sodium carboxymethyl cellulose may also be employed in the compositions of the present invention.
Other fatty acids, that may be employed in the present invention, include caprylic, capric, lauric, myristic, myristoleic, palmitoleic, oleic, ricinoleic, linoleic, linolenic, eleostearic, arachidic, arachidonic, behenic and erucic acid. The fatty acids of the present invention can be derived from naturally occurring or synthetic fatty acids; they can be saturated or unsaturated, including positional and geometric isomers, depending on the desired physical properties, for example liquid or solid.
In one preferred embodiment the composition of the present invention comprises a mixture of a phytostanol and/or a phytostanol ester and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof. The composition of the present invention may further comprise a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
One preferred embodiment of the present invention comprises a mixture of a phytostanol and/or a phytostanol ester and fatty acid alcohol, preferably, octadecanol. Another preferred embodiment of the present invention comprises a mixture a phytostanol and/or a phytostanol ester, Tween 60 and PEG. Other preferred embodiments include a phytostanol and/or a phytostanol ester, fatty acid alcohol and sucrose fatty acid ester, such as Crodesta.
One preferred embodiment of the present invention provides a method of reducing cholesterol absorption in humans which comprises orally administering an effective amount of a composition of the present invention. The invention also provides for a method for reducing serum cholesterol levels comprising administering a mixture of a phytostanol and/or a phytostanol ester and a surfactant(s).
In another embodiment of the present invention, emulsifiers may be used in the formulation of dispersible stanol and/or stanol ester systems. Preferred emulsifiers include a variety of phospholipids, phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), N-acylphosphatidyl ethanolamine (NAPE), phosphatidyl serine (PS), phosphatidyl inositol (PI), phosphatidyl glycerol (PG), diphosphatidyl glycerol (DPG), phosphatidic acid (PA) and plasmalogen.
These and other phospholipids are described, for example, in Szuhaj and List (eds.), Lecithins, American Oil Chemists Society (1985) ("Szuhaj and List"), incorporated herein in its entirety by reference.
The phospholipids may be used individually or in various combinations, and may be obtained from "natural" sources (e.g., soybean lecithin) or from chemical synthesis. The phospholipids may be in the form of relatively unpurified mixtures of phospholipids and other constituents (e. g., crude commercial lecithins obtained from the refining of soybean oil and other vegetable oils such as sunflower and canola), or may be purified to various degrees. In addition, phospholipids including those found in crude soybean lecithins or other crude commercial lecithins may be chemically modified. Lecithins, other phospholipid preparations, or individual phospholipids purified from natural sources or obtained by chemical synthesis, contain one or more functional groups susceptible to chemical modification, e.g., carbon-carbon double bonds, esters, phosphonate esters, amines and hydroxyl groups. Chemical modification of phospholipids can be compatible with the present methods. Thus, phospholipids that have been acetylated, hydroxylated, hydrolyzed (e. g., to produce lysophospholipids), hydrogenated, halogenated, phosphorylated, sulfated epoxidated, ethoxylated, or otherwise modified are potentially useful in the present methods and are included within the meaning of the term "phospholipid" as used herein. Various natural and synthetic phospholipids, including various types of lecithins, may be obtained commercially, for example Ultralec from ADM Corp., and other lecithins may be obtained from CALBIOCHEM~, La Jolla, Calif., USA and from SIGMA~
Chemical Company, St. Louis, Mo., USA.
In common usage, the term "lecithin" refers to the entire phospholipid fraction obtained from natural sources such as soybean, cotton seed, corn, wheat germ, oat, barley, sunflower, rapeseed, canola, linseed, peanut, palm kernel, egg yolk, milk and brain. Generally these fractions include a mixture of polar and neutral lipids with a polar lipid content (as defined by insolubility in acetone) of at least 50~. The art has also used the term "lecithin" as the common name for phosphatidyl choline. The term "lecithin"as used herein refers to the first usage, i.e., the entire phospholipid fraction obtained from selected vegetable oils or other appropriate sources. See, Chapter 2 of Szuhaj and List. It is to be noted, however, that phosphatidyl choline is an appropriate phospholipid for use in the present methods, either alone or in combination with other phospholipids.
Commercial soybean lecithin, a preferred source of phospholipids, is obtained from the refining of soybean oil.
Crude soybean oil generally contains about 1.0 to 3.0 weight percent phospholipids. When the crude oil is refined, the first step generally is to remove the phospholipids. This step, often called "degumming," is accomplished by first adding water to the crude oil. The water hydrates the phospholipids and makes them less soluble in the oil. The denser phospholipids and water are then separated from the less-dense oil, typically by centrifugation. Removal of the water from the dense phase results in a product having approximately equal amounts of phosphatidyl choline, phosphatidyl ethanolamine, and inositol phosphatides.
Partially refined soybean oil is commonly added back to produce a liquid product that is flowable at room temperature (sometimes called "fluidized lecithin").
Commercial fluid soybean lecithin contains about 50 to about 65 weight percent phospholipids and a small amount (generally less than about 5 weight percent) of various carbohydrates, mineral salts, protein materials, free fatty acids, sterols, and water. The remainder of commercial soybean lecithin is soybean oil.
Various lecithin powders enriched for phospholipid content are available commercially and may also be used in the present methods. Such lecithin powders are also within the scope of the term "lecithin" as used herein. The powders are typically derived by fractionation, for example acetone fractionation, of crude lecithins such as commercial soybean lecithin, and may contain from about 60~ to over 95~
phospholipid.
Another commercial source of phospholipids is the class of products, resulting from modification of soybean lecithin to improve its hydrophilic properties. Various approaches have been taken to effect these modifications. For example, soybean lecithin may be chemically or ezymatically modified, e.g., via reaction with malefic anhydride. Certain components may be removed from commercial soybean lecithin.
Alternatively, another approach is to add various components, for example nonionic emulsifiers, to the commercial soybean lecithin. Such emulsifiers include, without limitation, polyoxyalkylene monoglyceride, polyoxyalkylene diglycerides, and the polyoxyethylene derivatives of partial fatty acid esters. These modified lecithins are also included in the term "lecithin" as used herein.
Hydroxylated lecithin is a preferred embodiment of the phospholipids used in the invention. Hydroxylated lecithin is prepared by hydroxylating the double bonds in the fatty acids attached to the phospholipids and glycolipids of lecithin, which can be carried out by reaction with hydrogen peroxide and a weak acid such as lactic acid. Although not wishing to be bound by theory, it is believed that hydroxylation is not specific and can occur at any double bond within any of the lipids. The degree of hydroxylation is typically about 10$ but can be varied by methods known to those of ordinary skill in the art.
The compositions of the present invention are preferably formed into a fine dispersion using melt processing. One particular preferred method of melt processing comprises dry-mixing a phytostanol and/or a phytostanol ester and a surfactants) together with a stirring device such as a mechanical stirrer, shear mixer, vibrational mixer or sonicator. The mixture is then heated to a temperature sufficient to melt same, but not so high as to degrade the phytostanol, phytostanol ester or surfactant(s). The resulting mixture is then rapidly cooled, e.g., liquid nitrogen, to form a salt like material. While not wishing to be limited by theory, it is believed that the step of melt blending the phytostanol and/or phytostanol ester and surfactants) prior to rapid cooling facilitates the formation of a composition that is in a finely dispersed state that is able to reach the small intestine thereby being able to inhibit the absorption of cholesterol.
An alternative variation on the melt processing described above comprises the addition of a surfactants) to a phytostanol and/or phytostanol ester melt. This may be desirable in cases where the surfactants) is thermally unstable and would not survive prolonged heating at high temperatures, i.e., thus the residence time for the surfactants) is reduced by its later addition to phytostanol melt. Once the surfactants) has been added to the melt, the mixture can be treated in a fashion similar to that described previously.
A further alternative procedure to melt blending for forming the compositions of the present invention is high pressure melting. This procedure is also desirable for blending heat sensitive surfactants) and phytostanol and/or phytostanol esters. It has been discovered that by using a mixing or compression means allowing for increasing the pressure on the ingredients, the surfactants) phytostanol and/or phytostanol esters will melt blend at ambient temperatures.
Homogenous mixtures of heat sensitive surfactants) and phytostanol and/or phytostanol esters can therefore be formed while avoiding temperatures at which thermal decomposition of ingredients will occur.
One embodiment of high pressure melting is roller compaction, where the surfactants) and phytostanol and/or phytostanol ester are mixed together as described previously. The mixture is then compressed together using a roller such that the pressure exerted on the mixture is high enough to result in the flow of the ingredients and surface sintering of the mixture results.
An additional embodiment of high pressure melting is extrusion. For example, in an extrusion process, a loosely packed powder mixture of surfactants) and phytostanol and/or phytostanol ester, is propelled continuously along a screw through regions of high pressure and controlled temperature. Shear forces from the screw melt and mix the material into a continuous stream of molten material, which is then forced through a die.
The mixture resulting from the high pressure melting process is typically a soft, pliable solid material that can be further processed by cooling to solidify followed by breaking into chips or milling to form a uniform powder for use in the formation of products as described herein.
Mixtures of a phytostanol and/or a phytostanol ester and surfactants) may also be processed using solution processing or steric stabilization. Use of solution processing is particularly effective for use with surfactants) that are thermally stable. The phytostanol and/or phytostanol ester and surfactants) are generally dry mixed together, although this is not always necessary, the resulting solid mixture is then dissolved in an organic solvent, such as methylene chloride. The solvent is then removed to provide an amorphous/dispersible solid form.
Steric stabilization provides an effective method to form a dispersible solid form of a phytostanol and/or phytostanol ester and surfactant(s). A fine dispersion of a phytostanol and/or phytostanol ester is added to water containing the surfactant(s). The surfactants) in the water help to keep the stanol(s) in suspension. Once a finely divided suspension has formed the water is evaporated off leaving a more readily dispersible solid form.
Preferred embodiments of the present invention include a mixture of from about 10 to about 99.99 weight percent of a phytostanol and/or phytostanol ester and from about 0.01 to about 90 weight percent of a surfactant(s), preferably from about 40 to about 95 weight percent of a phytostanol and/or phytostanol ester and from about 5 to about 60 weight percent of a surfactant(s), and more preferably about 95 weight percent of a phytostanol and/or phytostanol ester and about 5 percent by weight percent of a surfactant(s).
In one preferred embodiment of the present invention, the compositions of the present invention comprise a phytostanol and/or phytostanol ester and at least two surfactants. Such a mixture comprises from about 10 to about 99.99 weight percent of a phytostanol and/or phytostanol ester and the sum of the at least two surfactants is from about 0.01 to about 90 weight percent, preferably such a mixture comprises from about 40 to about 95 weight percent of a phytostanol and/or phytostanol ester and the sum of at least two surfactants is from about 5 to about 60 weight percent, and more preferably about 95 weight percent of a phytostanol and/or phytostanol ester and the sum of at least two surfactants is about 5 weight percent.
Desirable characteristics of food additive compositions for reducing cholesterol absorption include absence of side effects, efficacy without absorption of the compound, stability at cooking temperatures, stability in storage and in oxidizing environments, low cost, availability, and small dose requirements.
The compositions of the present invention may be orally administered in a variety of forms: uncoated tablets, coated tablets such as film, sugar or gelatin coated, chewable tablets, swallowable tablets (capsules), effervescent tablets, immediate release tablets, sustained (controlled or modified) release tablets; soft gelatin capsules either liquid (non-aqueous) or paste (slurry); hard gelatin capsules in powder (granulation), bead, tablet, liquid, semi-solid, sprinkle (immediate or controlled release) forms; oral liquids such as aqueous, emulsions or suspension; sachets (packages) in powder, granule or sprinkle (immediate or controlled release) forms. Other forms for administering the compositions of the present invention include syrup, fruit beverages, or fruit gelatines.
Although the composition of the invention may be used in various embodiments it may be said, one preferred embodiment is when the compositions of the present invention are evenly distributed in finely divided form throughout the food product or beverage to which it is added. The compositions of the present invention may be added to food products or beverages prior to purchase by the consumer for consumption.
Alternatively, the compositions of the present invention may be purchased in bulk form or individually wrapped packages, e.g., 8 oz. servings. A serving from the bulk form, e.g., 8 oz., or the contents of a package may be added to a glass of cold or hot water or other beverage, stirred to dissolve the contents, prior to consumption. Typical beverages include the following, instant ice tea in Orange Pekoe, English Breakfast, Passion Fruit and Hisbiscus Flavors, powdered soft drinks such as Crystal Light and Contry Time Lemonade, Instant Iced Coffee in flavors such as Mocchacchino, Hazelnut, French Vanilla, and Hot Chocolate and Fruit Smoothies.
The compositions of the present invention may also be included in mini-sweets. The mini-sweets will typically be consumed after any and all meals of each day. The mini-sweets will typically contain between 25 and 60 calories and 1 to 3 grams of fat. Mini-sweets include the following varieties: chocolate chews; caramel chews; hard candies such as cinnamon, butterscotch, coffee and fruit flavors;
chocolate truffles such as hard dark chocolate on the outside filled with hazelnut creme, Irish creme or cappucinno creme; brownie bites; cookie chews in peanut butter, chocolate chip or ginger snaps; granola/nutrition bar miniatures such as chocolate covered oat and peanut butter; chewy breath mints; mint meltaways; and mini-pudding. Mini-sweets may be prepared in individually wrapped packages or in larger containers for multiple uses.
The method by which the novel food additive composition, i.e., the stanol and/or stanol ester and surfactant(s), is used to reduce cholesterol absorption from foods and beverages includes the step of commingling the food additive composition with foods and beverages, mixing until uniformly blended.
In a preferred method of commingling the indicated food additive with foods and beverages which contain cholesterol, the food additive is added such that the amount of stanols in the food additive is in the ratio of about 1:1 by weight to the cholesterol contained in the foods and beverages.
Thus, for a food additive composition which comprises 25$
stanols and a food which contains about 0.1~ cholesterol (such as hamburger), the ratio of food additive to food product is about 1:250 by weight.
The food additive composition of the invention can be commingled with foods by a step selected from the group of infusion, injection, mixing, kneading, blending, immersion, spraying, surface application (for example, brushing and basting), cooking in oils which contain the food additive-invention, and combinations thereof. Preferred steps for commingling the food additive-invention with ground meat are kneading and mixing; for meat pieces such as steaks, chicken breasts, and chopped, diced or sliced meat, the preferred steps are injection, infusion, spraying, immersion, and surface applications such as basting and marinating. Two preferred steps for commingling the food additive-invention with beverages are mixing and blending.
The compositions of the present invention will be used as food additives to foods such as meats, eggs and dairy products. Generally, when used as food additives, the compositions of the present invention will not contribute substantially to the taste of the food product.
Accordingly, the compositions of the present invention can be used in food products without compromising the food products taste and flavor.
The compositions of the present invention may also be formulated into fine particles which may be sprinkled on to other food products, i.e., dairy products such as ice cream or candy.
The compositions of the invention may be administered to any animal. Foremost among such animals are mammals, e.g., humans, although the invention is not intended to be so limited. The dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
The compositions of the present invention may be administered orally in any of the usual solid forms such as pills, tablets, capsules or powders, including sustained release preparations. The term unit dosage form as used in this specification and the claims refer to physically discrete units to be administered in single or multiple dosage to animals, each unit containing a predetermined quantity of active material, i.e., phytostanol and/or phytostanol ester, in association with a surfactants) and a carrier. The quantity of active material is that calculated to produce the desired therapeutic effect upon administration of one or more of such units. Of course, it is understood that the exact treatment level will depend upon the case history of the animal, e.g., human being, that is treated. The precise treatment level can be determined by one of ordinary skill in the art without undue experimentation.
The require dosage of the phytostanol and/or phytostanol ester will vary with the severity of the condition and the duration of the treatment. Unit dosages can range from about 0.01 mg/kg to about 500 mg/kg (the unit designated "mg/kg" as used herein refers to mg of phytostanol and/or phytostanol ester per kilogram of body weight), preferably from about 0.1 mg/kg to about 125 mg/kg with up to six doses daily, preferably four dosages daily. Most preferably, the doses are administered at meal times. The dosages may be administered orally in any suitable unit dosage form such as pills, tablets, and capsules. Preferred are capsules made from gelatin.
As used herein, the term "carrier" denotes a solid or liquid filler, diluent, or encapsulating substance. Some examples of the substances that can act as carriers are sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc;
stearic acid; magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and of the broma; polyols such as propylene glycol, glcerin, sorbitol, mannitol, and polyethylene glycol; agar, alginic acid; pyrogen-free water; isotonic saline; ethyl alcohol and phosphate buffer solutions, as well as other non-toxic compatible substances used in preparation of formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, and preservatives can also be present.
Dye stuffs or pigments may be added to the tablets, for example, for identification or in order to characterize combinations of active doses Other preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules, which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.
Powders are prepared by comminuting the compositions of the present invention to a suitable fine size and mixing with a similarly comminuted diluent pharmaceutical carrier such as an edible carbohydrate material as for example, starch.
Sweetening, flavoring, preservative, dispersing and coloring agents can also be present.
Capsules are made by preparing a powder mixture as described above and filling formed gelatin sheaths. A lubricant such as talc, magnesium stearate and calcium stearate can be added to the powder mixture as an adjuvant before the filling operation; a glidant such as colloidal silica may be added to improve flow properties; a disintegrating or solubilizing agent may be added improve the availability of the medicament when the capsule is ingested.
Tablets are made by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compositions of the present invention, suitable comminuted, with a diluent or base such as starch, sucrose, kaolin, dicalcium phosphate and the like. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acacia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the resulting imperfectly formed slugs broken into granules.
The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The medicaments can also be combined with free flowing inert carriers and compressed into tablets directly without going through the granulating or slugging steps. A protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dye stuffs or pigments may be added to the tablets, for example, for identification or in order to characterize combinations of active doses. In tablet form the carrier comprises from about 0.1$ to 99~ by weight of the total composition.
This invention will be better understood from the Examples which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention and no limitation of the invention is implied.
Soy sitostanol (AC Humko, NF00114) (1g) was physically mixed with an equal weight of sodium dioctylsulfosuccinate (Aldrich Chemicals). The blend was melted at 170°C to form a clear solution. The clear solution was rapidly cooled by pouring it into liquid nitrogen. A crystalline transparent salt was obtained. The salt (2g) was added to water (8g) to give a milky-white emulsion with no visible particles. The solubility of the crystalline was found to be 1200 micrograms per ml using the dissolution assay described below. (Maximum solubility of cryground beta-sitostanol in the dissolution assay was found to be 300 micrograms per ml.) Dissolution Assay A stock dissolution solution (5X) was prepared comprising taurocholic acid, Na2+ (500 mM, Sigma, cat# T4009), 2-monoolein (10 mM, Nu-Check Prep, cat# M-239), oleic acid, free (10 mM, Sigma cat# 01008) in cholorform:MeOH (1:1). A
buffer solution was prepared comprising O.O1M sodium phosphate buffer with 3 mM sodium azide, pH 7.4.
In order to prepare the dissolution solution for use in the dissolution assay 1 ml of the 5X stock dissolution solution in a 20 ml vial was dried down under an NZ stream at 50°C.
The dried down dissolution solution was then redried twice from 2 ml ethyl ether with vortexing of the vial following each addition. Excess ether was then driven off by drying the vial for 1 hour at 100°C in an oven.
The vial with the dried down dissolution solution was rehydrated with 5 ml of the sodium phosphate buffer.
Nitrogen was bubbled through the solution for 5 minutes to ensure complete removal of ether. The final concentrations of the dissolution constituents were taurocholic acid (100 mM), 2-monoolein (2 mM), oleic acid ~2 mM) in sodium phosphate (0.01 M, pH 7.4) with 3 mM NaN3.
In order to determine the solubility of the blend of the present Example, a sample of the blend having an equivalent of 100 mg sitostanol was added to the vial with the 5 ml of the rehydrated dissolution solution. The contents of the vial were gently swirled and then placed in rotating incubator. A 100 mg cholesterol sample was prepared for assaying in the same manner as the blend of the present Example, as well as a 100 mg sample of cryoground stanol.
At 4 hours a 1.0 ml aliquot was removed from each vial. The aliquots were immediately filtered through a 0.2 arm syringe filter.
Using a Cholesterol CII Enzymatic Kit (Wako Pure Chemical Industries, Ltd.) the amount of stanol dissolved in the filtered dissolution solution was determined according to the following protocol. Note that the concentration of stanol is given as the amount of unesterified stanol.
1. A 2X color reagent was prepared by adding only one-half the recommended buffer solution to the supplied lyophilized color reagent.
2. A 0.2 mg/ml sitostanol standard was prepared by aliquoting sitostanol from a 1:1 CHC13/MEOH stock and adding triton-X 100 for a final rehydrated concentration of 2.0~
Triton, 0.2 mg/ml sitostanol. This solution was vortexed and dried down under a NZ stream at 50°C, followed by redrying twice from ethyl ether. The sample was rehydrated in of 0.01 M sodium phosphate buffer with 3 mM NaN3, pH 7.4.
The mixture was then vortexed.
4. A 96 well plate was setup. The first two columns were used for the standard. Each sample was run in quadruplicate.
5. Samples for a standard curve were formed by adding water to the well first followed by the standard according to the proportions outlined in the table below:
Water Sitostanol Sitostanol (ml) Standard (mg) (ml) 97.5 2.5 0.5 6. Samples (5 microliter) were added to wells containing water so that the final volume was 100 ml.
7. The 2X color reagent was added to each of the wells using a multi-pipettor. Care should be taken to avoid contact with the solutions by touching the pipet tips at the top edges of the well wall.
8. The reagents were then mixed by shaking on a plate shaker (cover with plate sealing plastic). The plates were incubated at 37°C for 15 min.
9. The plate was removed from the incubator and an ELISA
reader at 500 nm (within 1 hour of plates removal from the incubator) was used to read the plate and thereby determine the solubility of the sample in the dissolution solution.
The formulation (20g) of Example 1 was dispersed in water (100 mL) in a high speed blender prior to mixing with hamster chow containing 10~ by weight corn oil (0.24 cholesterol). The dispersion was added to the hamster chow to give 2~ by weight stanol equivalent. Hamsters were fed diet for 7 days and fecal cholesterol levels were determined on the last 48 hours pooled samples. Fecal cholesterol ratio ("FC Ratio") for each sample, formulated stanol and unformulated stanol (control), is determined by dividing their cholesterol measurement by the cholesterol measurement for hamsters fed hamster chow with 10~ by weight corn oil and 0.24 cholesterol (containing chow only). Comparison of FC Ratios relative to the control, 2~ by weight of unformulated stanol equivalent, showed that the hamsters fed the chow with the formulation from Example 1 absorbed less cholesterol, i.e., larger FC ratio. The results are shown in Table 1.
Formulation FC Ratio Control 3.1 Example 1 3.8 Table 1 Additional studies were conducted using dispersions of the formulation prepared in Example 1 having 1~ by weight stanol equivalent in hamster chow as described above. Results indicated that chow with 1$ by weight stanol equivalent had enhanced fecal cholesterol ratios relative to the control.
Note that some variability between FC Ratios will be observed due to the use of different hamsters in studies.
The results are shown in Table 2.
Formulation FC Ratio Control 3.1 Example 1 4.4 Table 2 Evaluation of the efficacy of the formulations of the present invention to inhibit the absorption of cholesterol in the intestine was conducted using male beagle dogs. The dogs had an approximate weight of 8 to 12 kg at the start of the study and were approximately 11 to 13 months old at the time of purchase. The dogs were housed in individual, stainless steel cages. The cages were modified for the separation of urine and feces and the collection of feces during the fecal collection periods.
During the acclimation and washout periods the dogs were fed certified canine diet #5007 (PMI Feeds, Inc.). During the testing period, days 1-4, the dogs were fed certified canine diet #5007, supplemented with 0.25$ cholesterol made by Ed Uhlman at Research Diets, Inc. New Brunswick, NJ. All diets were offered for approximately 2 to 4 hours daily at approximately the same time each day. Water was provided ad libitum. The animal room's environment was maintained at a temperature of 18° to 29°C, a relative humidity of 50~ ~
20~, and a 12-hour light/12-hour dark cycle.
The following formulations were tested: a control sample of stanol in a push-fit gelatin capsule and a 50 weight cremophor/50 weight ~ soy stanol blend, which was prepared by co-melting the cremophor and stanol together at 180°C and rapidly quenching the melt in liquid nitrogen to afford a transparent crystalline salt. The salt was ground to a fine powder using a cryo-mill and placed in a push-fit gelatin capsule for administration. A 9~ AOT/9~ PEG/72~ soy sitostanol blend formulation by solution blending in chloroform. The chloroform was then evaporated to give an amorphous material, which was cryo-milled into a fine powder. The powder was placed in a push-fit gelatin capsule for administration. Animals were dosed at 63 mg/kg stanol equivalence.
Each animal received the cholesterol-supplemented diet and the formulations of the present invention in gelatin capsule form daily for 4 days. The gelatine capsules and controls were offered at approximately the same time each day, before the animals were fed in on each day.
Pre-test fecal samples were collected for 72 hours before test formulation administration and on test days 3, 4 and 5.
Samples were collected before feed in (and before administration of the samples and control) each day, transferred to plastic containers, and pooled at 3-day intervals. The fecal cholesterol level in each of the collected samples was then determined using liquid chromatography mass-spectrometry ("LC-MS").
Formulation (Ref.) FC Ratio Control (Stanol) 0.95 50~ Cremophor/50~ stanol (A) 1.43 9~ AOT/9~ PEG/72~ stanol (B) 1.95 Table 3 Ingredient Amount (mg) Stanol 600 1-Octadecanol 31.58 Ac-Di-Sol 91.58 Crodesta F160 126.32 Stearic Acid 1.58 Stanol, 1-octadecanol (Aldrich, Milwaukee, WI), and half of the Ac-Di-Sol (croscarmellose sodium NF Type A, FMS Corp., Newark, Delaware) were mixed in a V-blender (Model # Twin Shell Dry Blender 4QT, Patterson-Kelly Co., East Stroudsbourgh, PA) for 5 minutes into a powder mixture. The resulting mixture was compacted in a TF-Miniroller compactor (Model No. TF-Mini, Vector Corp., Marion, Iowa; 180 kg/cmz of pressure, feed speed of 10 RPM and roller speed of 7 RPM) resulting in sintering and melting of the mixture. The compacted material was then passed through a Comil (Model No. 197.5, Quadro Engineering Inc., Waterloo, Canada). The powder was then mixed with the reminder of the Ac-Di-Sol and Crodesta F-160 (sucrose stearate, Croda, Inc., Mill Hall, PA), followed by blending with the V-blender for 5 minutes.
The stearic acid (triple pressed, Mallinckrodt Baker, Inc., Phillipsbury, NJ), which was first passed through a 40 mesh sieve, was added to the blend in the V-blender and mixed for 3 minutes. The resulting mixture is then tableted by compression in a standard tablet press.
The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 4 1.08 Table 4 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 Crodesta F160 120 Ac-Di-Sol 90 Avicel PH-102 25 Sodium Palmitate 50 Stearic Acid 6 Avicel PH-102 is microcrystalline cellulose and is available from FMC Corp., Newark, Delaware.
The fecal cholesterol ratio for this formulation was compared to Benecol as a control. Benecol is a spread that incorporates plant stanol esters, as a method to promote healthy cholesterol levels and is available from McNeil Consumer Healthcare, Ft. Washington PA. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 5 1.14 Table 5 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 1-Octadecanol 30 Hydroxylated Lecithin 60 Sodium Palmitate 60 Ac-Di-Sol 85 Avicel PH-102 25 Crodesta F160 10 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 6 1.16 Table 6 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 380 1-Octadecanol 20 Hydroxylated Lecithin 50 Ac-Di-Sol 38 Crodesta F160 42 Avicel PH-102 14 Stearic Acid 3 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.10 (Benecol) Example 7 1.30 Table 7 Deoiled Hydroxylated lecithin (10g, Central Soya) was dispersed in water (30g) using a high speed blender.
Hammer-milled stanol (20g) was added to the dispersion and the mixture was once again blended under high shear. The resulting mixture was dried at 70°C at reduced pressure (6 inches, Hg) overnight in a vacuum oven. The resulting mixture was hammer-milled to obtain a fine powder. The solubility of the powder was found to be 750 mg per mL using the dissolution assay described in Example 1.
A push-fit gelatin capsule was prepared using the powder having a dosage of 63 mg stanol per kg of dog weight. The efficacy of the prepared gelatin capsule containing the powder was compared to a benecol at the same stanol dosage level. The benecol was delivered to the dog in liquid form using a syringe. The FC ratio for the dog dosed with powder prepared in this Example was determined and compared to the FC ratio for a control dog dosed with benecol. The results are shown in Table 8.
Formulation FC Ratio Control (Benecol) 1.17 Example 8 1.57 (stanol/hydroxylated lecithin) Table 8 A formulation containing lecithin in place of hydroxylated lecithin was formulated as in Example 8. The FC rations determined for the formulation compared to Benecol from a dog study administered in the same manner as Example 8 are shown below:
Formulation FC Ratio Control (Benecol) 1.29 Example 9 1.3 (stanol/lecithin) Table 9 Compressed tablets comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 Crodesta F160 88.42 Ac-Di-Sol 60 Avicel PH-102 49.26 Stearic Acid 5.68 Tween 60 31.58 PEG 3350 Powder 30.32 Table 10 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.06 (Benecol) Example 10 1.14 Table 11 33.47 grams of the ocadecanoic acid ester of stanol was dissolved in 250 ml of chloroform. 1.05 grams of octadecanol was dissolved added to chloroform solution with heating at 51 degrees C to facilitate dissolution. The chloroform was removed by evaporation under nitrogen yielding a solid mixture containing 3.04 octadecanol. The mixture was cryo-ground into hamster chow and fed to hamsters at 1 percent stanol equivalent in their diet. The hamsters who consumed the chow with stanol ester were found to have absorbed less cholesterol than a control group of hamsters that eat hamster chow without stanol ester.
Example 12 Hydroxylated lecithin powder (Precept 8120, Central Soya) was combined with stanol powder (AC Humko NF00114) to give a mixture containing 70~ w/w stanol and 30~ w/w hydroxylated lecithin. The mixture was extruded using a Prism twin screw which allows for temperature control over four zones and the die end. For this example zone temperatures 1 through 4 were set to 65°C. The die temperature was set to 90°C and the screw speed set to 200 rpm. Approximately 100 grams of this material was extruded in long spaghetti like rods which were too soft and brittle to be processed through a chopper.
The rods were hammer milled into a free flowing powder under liquid nitrogen. Hard gelatin capsules were filled with the powdered lecithin/stanol product and tested for cholesterol absorption inhibition in the standard dog model described above in Example 3. Dose-response results are shown in Table 12, indicating performance statistically better than control at 30, 120 and 360 mg/Kg.
Formulation Cholesterol Excreted (ug/g feces/day) Control 656.03 Benecol 867.53 (60 mg/kg) Example 12 814.88 (30 mg/kg) Example 12 758.03 (60 mg/kg) Example 12 1083.19 (120 mg/kg) Example 12 1114.65 (360 mg/kg) Table 12 Example 13 Sodium stearate (Witco) was added to a 70:30 mixture of stanol:hydroxylated lecithin powder prepared as in Example 12 to give 16.7 w/w stearate. The powders were fed into a Prism twin screw extruder using a vibrating feeder.
Temperatures of zones 1 to 4 were set at 50, 57, 68 and 91°C
respectively (the actual temperatures measured in zones 2-4 were 57, 69 and 99°C, respectively). The die temperature was set to 110°C (actual temperature 102°C). The screw speed was set to 100 RPM. As in Example 12, spaghetti-like rods were extruded and hammer milled to yield a free-flowing powder. The powder was incorporated into gelatin capsules and tested for cholesterol absorption in the dog model discussed in Example 3.
Example 14 A mixture of stanol 62$ (w/w) (AC Humko), hydroxylated lecithin 30g (w/w) (Precept 8120, Central Soya) and Ac-Di-Sol 8~ (w/w)(croscarmellose sodium NF Type A, FMS Corp., Newark, Delaware) was compressed using roller compaction and then co-milled. The resultant powder had sufficient bulk density to enable filling a gel capsule with at least 400 mg of stanol. The material was tested for cholesterol absorption in the dog model discussed in Example 3.
Formulation Cholesterol Excreted (pg/g feces/day) Control 397 Benecol 477 (60 mg/kg) Benecol Soft Gel 534 (60 mg/kg) Example 14 554 (60 mg/kg) Example 14 550 (120 mg/kg) Example 14 653 (240 mg/kg) Table 13 Example 15 The following tablet formulations were prepared.
Formulation A
Ingredient Conc. ~ (w/w) mg/tablet Spray chilled 65.80 526.4 stanol/octadecanol Sucrose, NF 16.66 133.3 (SugarTab) Microcrystalline 11.00 88.0 Cellulose, NF
(Avicel PH-102) Croscarmellose 6.00 2.7 Sodium, NF (Ac-Di-Sol) Sodium Lauryl 0.34 2.7 Sulfate, NF
Stearic Acid, NF 0.20 1.6 Totals 100.00 800.0 Formulation B
Ingredient Conc. $ (w/w) mg/tablet Spray chilled 69.5 556.0 stanol/octadecanol /Tween-601 Sucrose, NF 13.3 106.4 (SugarTab) Microcrystalline 11.0 88.0 Cellulose, NF
(Avicel PH-102) Croscarmellose 6.0 48.0 Sodium, NF (Ac-Di-Sol) Stearic Acid, NF 0.2 1.6 Totals 100.0 800.0 lEquivalent to 27.8 mg for each of the octadecanol and Tween 60 per tablet.
Formulation C
Ingredient Conc. ~ (w/w) mg/tablet Spray chilled 74.05 631.6 stanol/octadecanol Sucrose 14.81 126.3 Monostearate, FCC
(Crodesta F-160) Croscarmellose 10.74 91.6 Sodium, NF (Ac-Di-Sol) D&C Yellow #10 0.21 1.8 Lake Stearic Acid, NF 0.19 1.6 Totals 100.00 852.9 Formulation D
Ingredient Conc. $ (w/w) mg/tablet Spray chilled 36.72 315.79 stanol/octadecanol Sucrose, NF 50.09 430.79 (SugarTab) Sucrose 7.34 63.16 Monostearate, FCC
(Crodesta F-160) Croscarmellose 5.32 45.79 Sodium, NF (Ac-Di-Sol) D&C Yellow #10 0.24 2.10 Lake Stearic Acid, NF 0.28 2.37 Totals 100.00 860.00 Other objects, advantages, features, modifications of this invention will be apparent to those of ordinary skill in this art. This invention is not limited except as set forth in the following claims.
reader at 500 nm (within 1 hour of plates removal from the incubator) was used to read the plate and thereby determine the solubility of the sample in the dissolution solution.
The formulation (20g) of Example 1 was dispersed in water (100 mL) in a high speed blender prior to mixing with hamster chow containing 10~ by weight corn oil (0.24 cholesterol). The dispersion was added to the hamster chow to give 2~ by weight stanol equivalent. Hamsters were fed diet for 7 days and fecal cholesterol levels were determined on the last 48 hours pooled samples. Fecal cholesterol ratio ("FC Ratio") for each sample, formulated stanol and unformulated stanol (control), is determined by dividing their cholesterol measurement by the cholesterol measurement for hamsters fed hamster chow with 10~ by weight corn oil and 0.24 cholesterol (containing chow only). Comparison of FC Ratios relative to the control, 2~ by weight of unformulated stanol equivalent, showed that the hamsters fed the chow with the formulation from Example 1 absorbed less cholesterol, i.e., larger FC ratio. The results are shown in Table 1.
Formulation FC Ratio Control 3.1 Example 1 3.8 Table 1 Additional studies were conducted using dispersions of the formulation prepared in Example 1 having 1~ by weight stanol equivalent in hamster chow as described above. Results indicated that chow with 1$ by weight stanol equivalent had enhanced fecal cholesterol ratios relative to the control.
Note that some variability between FC Ratios will be observed due to the use of different hamsters in studies.
The results are shown in Table 2.
Formulation FC Ratio Control 3.1 Example 1 4.4 Table 2 Evaluation of the efficacy of the formulations of the present invention to inhibit the absorption of cholesterol in the intestine was conducted using male beagle dogs. The dogs had an approximate weight of 8 to 12 kg at the start of the study and were approximately 11 to 13 months old at the time of purchase. The dogs were housed in individual, stainless steel cages. The cages were modified for the separation of urine and feces and the collection of feces during the fecal collection periods.
During the acclimation and washout periods the dogs were fed certified canine diet #5007 (PMI Feeds, Inc.). During the testing period, days 1-4, the dogs were fed certified canine diet #5007, supplemented with 0.25$ cholesterol made by Ed Uhlman at Research Diets, Inc. New Brunswick, NJ. All diets were offered for approximately 2 to 4 hours daily at approximately the same time each day. Water was provided ad libitum. The animal room's environment was maintained at a temperature of 18° to 29°C, a relative humidity of 50~ ~
20~, and a 12-hour light/12-hour dark cycle.
The following formulations were tested: a control sample of stanol in a push-fit gelatin capsule and a 50 weight cremophor/50 weight ~ soy stanol blend, which was prepared by co-melting the cremophor and stanol together at 180°C and rapidly quenching the melt in liquid nitrogen to afford a transparent crystalline salt. The salt was ground to a fine powder using a cryo-mill and placed in a push-fit gelatin capsule for administration. A 9~ AOT/9~ PEG/72~ soy sitostanol blend formulation by solution blending in chloroform. The chloroform was then evaporated to give an amorphous material, which was cryo-milled into a fine powder. The powder was placed in a push-fit gelatin capsule for administration. Animals were dosed at 63 mg/kg stanol equivalence.
Each animal received the cholesterol-supplemented diet and the formulations of the present invention in gelatin capsule form daily for 4 days. The gelatine capsules and controls were offered at approximately the same time each day, before the animals were fed in on each day.
Pre-test fecal samples were collected for 72 hours before test formulation administration and on test days 3, 4 and 5.
Samples were collected before feed in (and before administration of the samples and control) each day, transferred to plastic containers, and pooled at 3-day intervals. The fecal cholesterol level in each of the collected samples was then determined using liquid chromatography mass-spectrometry ("LC-MS").
Formulation (Ref.) FC Ratio Control (Stanol) 0.95 50~ Cremophor/50~ stanol (A) 1.43 9~ AOT/9~ PEG/72~ stanol (B) 1.95 Table 3 Ingredient Amount (mg) Stanol 600 1-Octadecanol 31.58 Ac-Di-Sol 91.58 Crodesta F160 126.32 Stearic Acid 1.58 Stanol, 1-octadecanol (Aldrich, Milwaukee, WI), and half of the Ac-Di-Sol (croscarmellose sodium NF Type A, FMS Corp., Newark, Delaware) were mixed in a V-blender (Model # Twin Shell Dry Blender 4QT, Patterson-Kelly Co., East Stroudsbourgh, PA) for 5 minutes into a powder mixture. The resulting mixture was compacted in a TF-Miniroller compactor (Model No. TF-Mini, Vector Corp., Marion, Iowa; 180 kg/cmz of pressure, feed speed of 10 RPM and roller speed of 7 RPM) resulting in sintering and melting of the mixture. The compacted material was then passed through a Comil (Model No. 197.5, Quadro Engineering Inc., Waterloo, Canada). The powder was then mixed with the reminder of the Ac-Di-Sol and Crodesta F-160 (sucrose stearate, Croda, Inc., Mill Hall, PA), followed by blending with the V-blender for 5 minutes.
The stearic acid (triple pressed, Mallinckrodt Baker, Inc., Phillipsbury, NJ), which was first passed through a 40 mesh sieve, was added to the blend in the V-blender and mixed for 3 minutes. The resulting mixture is then tableted by compression in a standard tablet press.
The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 4 1.08 Table 4 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 Crodesta F160 120 Ac-Di-Sol 90 Avicel PH-102 25 Sodium Palmitate 50 Stearic Acid 6 Avicel PH-102 is microcrystalline cellulose and is available from FMC Corp., Newark, Delaware.
The fecal cholesterol ratio for this formulation was compared to Benecol as a control. Benecol is a spread that incorporates plant stanol esters, as a method to promote healthy cholesterol levels and is available from McNeil Consumer Healthcare, Ft. Washington PA. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 5 1.14 Table 5 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 1-Octadecanol 30 Hydroxylated Lecithin 60 Sodium Palmitate 60 Ac-Di-Sol 85 Avicel PH-102 25 Crodesta F160 10 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.15 (Benecol) Example 6 1.16 Table 6 Push-fit capsules comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 380 1-Octadecanol 20 Hydroxylated Lecithin 50 Ac-Di-Sol 38 Crodesta F160 42 Avicel PH-102 14 Stearic Acid 3 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.10 (Benecol) Example 7 1.30 Table 7 Deoiled Hydroxylated lecithin (10g, Central Soya) was dispersed in water (30g) using a high speed blender.
Hammer-milled stanol (20g) was added to the dispersion and the mixture was once again blended under high shear. The resulting mixture was dried at 70°C at reduced pressure (6 inches, Hg) overnight in a vacuum oven. The resulting mixture was hammer-milled to obtain a fine powder. The solubility of the powder was found to be 750 mg per mL using the dissolution assay described in Example 1.
A push-fit gelatin capsule was prepared using the powder having a dosage of 63 mg stanol per kg of dog weight. The efficacy of the prepared gelatin capsule containing the powder was compared to a benecol at the same stanol dosage level. The benecol was delivered to the dog in liquid form using a syringe. The FC ratio for the dog dosed with powder prepared in this Example was determined and compared to the FC ratio for a control dog dosed with benecol. The results are shown in Table 8.
Formulation FC Ratio Control (Benecol) 1.17 Example 8 1.57 (stanol/hydroxylated lecithin) Table 8 A formulation containing lecithin in place of hydroxylated lecithin was formulated as in Example 8. The FC rations determined for the formulation compared to Benecol from a dog study administered in the same manner as Example 8 are shown below:
Formulation FC Ratio Control (Benecol) 1.29 Example 9 1.3 (stanol/lecithin) Table 9 Compressed tablets comprising a unit dosage form of a stanol were prepared as described in Example 4, having the following composition, Ingredient Amount (mg) Stanol 600 Crodesta F160 88.42 Ac-Di-Sol 60 Avicel PH-102 49.26 Stearic Acid 5.68 Tween 60 31.58 PEG 3350 Powder 30.32 Table 10 The fecal cholesterol ratio for this formulation was compared to Benecol as a control. The results are shown in the following table:
Formulation FC Ratio Control 1.06 (Benecol) Example 10 1.14 Table 11 33.47 grams of the ocadecanoic acid ester of stanol was dissolved in 250 ml of chloroform. 1.05 grams of octadecanol was dissolved added to chloroform solution with heating at 51 degrees C to facilitate dissolution. The chloroform was removed by evaporation under nitrogen yielding a solid mixture containing 3.04 octadecanol. The mixture was cryo-ground into hamster chow and fed to hamsters at 1 percent stanol equivalent in their diet. The hamsters who consumed the chow with stanol ester were found to have absorbed less cholesterol than a control group of hamsters that eat hamster chow without stanol ester.
Example 12 Hydroxylated lecithin powder (Precept 8120, Central Soya) was combined with stanol powder (AC Humko NF00114) to give a mixture containing 70~ w/w stanol and 30~ w/w hydroxylated lecithin. The mixture was extruded using a Prism twin screw which allows for temperature control over four zones and the die end. For this example zone temperatures 1 through 4 were set to 65°C. The die temperature was set to 90°C and the screw speed set to 200 rpm. Approximately 100 grams of this material was extruded in long spaghetti like rods which were too soft and brittle to be processed through a chopper.
The rods were hammer milled into a free flowing powder under liquid nitrogen. Hard gelatin capsules were filled with the powdered lecithin/stanol product and tested for cholesterol absorption inhibition in the standard dog model described above in Example 3. Dose-response results are shown in Table 12, indicating performance statistically better than control at 30, 120 and 360 mg/Kg.
Formulation Cholesterol Excreted (ug/g feces/day) Control 656.03 Benecol 867.53 (60 mg/kg) Example 12 814.88 (30 mg/kg) Example 12 758.03 (60 mg/kg) Example 12 1083.19 (120 mg/kg) Example 12 1114.65 (360 mg/kg) Table 12 Example 13 Sodium stearate (Witco) was added to a 70:30 mixture of stanol:hydroxylated lecithin powder prepared as in Example 12 to give 16.7 w/w stearate. The powders were fed into a Prism twin screw extruder using a vibrating feeder.
Temperatures of zones 1 to 4 were set at 50, 57, 68 and 91°C
respectively (the actual temperatures measured in zones 2-4 were 57, 69 and 99°C, respectively). The die temperature was set to 110°C (actual temperature 102°C). The screw speed was set to 100 RPM. As in Example 12, spaghetti-like rods were extruded and hammer milled to yield a free-flowing powder. The powder was incorporated into gelatin capsules and tested for cholesterol absorption in the dog model discussed in Example 3.
Example 14 A mixture of stanol 62$ (w/w) (AC Humko), hydroxylated lecithin 30g (w/w) (Precept 8120, Central Soya) and Ac-Di-Sol 8~ (w/w)(croscarmellose sodium NF Type A, FMS Corp., Newark, Delaware) was compressed using roller compaction and then co-milled. The resultant powder had sufficient bulk density to enable filling a gel capsule with at least 400 mg of stanol. The material was tested for cholesterol absorption in the dog model discussed in Example 3.
Formulation Cholesterol Excreted (pg/g feces/day) Control 397 Benecol 477 (60 mg/kg) Benecol Soft Gel 534 (60 mg/kg) Example 14 554 (60 mg/kg) Example 14 550 (120 mg/kg) Example 14 653 (240 mg/kg) Table 13 Example 15 The following tablet formulations were prepared.
Formulation A
Ingredient Conc. ~ (w/w) mg/tablet Spray chilled 65.80 526.4 stanol/octadecanol Sucrose, NF 16.66 133.3 (SugarTab) Microcrystalline 11.00 88.0 Cellulose, NF
(Avicel PH-102) Croscarmellose 6.00 2.7 Sodium, NF (Ac-Di-Sol) Sodium Lauryl 0.34 2.7 Sulfate, NF
Stearic Acid, NF 0.20 1.6 Totals 100.00 800.0 Formulation B
Ingredient Conc. $ (w/w) mg/tablet Spray chilled 69.5 556.0 stanol/octadecanol /Tween-601 Sucrose, NF 13.3 106.4 (SugarTab) Microcrystalline 11.0 88.0 Cellulose, NF
(Avicel PH-102) Croscarmellose 6.0 48.0 Sodium, NF (Ac-Di-Sol) Stearic Acid, NF 0.2 1.6 Totals 100.0 800.0 lEquivalent to 27.8 mg for each of the octadecanol and Tween 60 per tablet.
Formulation C
Ingredient Conc. ~ (w/w) mg/tablet Spray chilled 74.05 631.6 stanol/octadecanol Sucrose 14.81 126.3 Monostearate, FCC
(Crodesta F-160) Croscarmellose 10.74 91.6 Sodium, NF (Ac-Di-Sol) D&C Yellow #10 0.21 1.8 Lake Stearic Acid, NF 0.19 1.6 Totals 100.00 852.9 Formulation D
Ingredient Conc. $ (w/w) mg/tablet Spray chilled 36.72 315.79 stanol/octadecanol Sucrose, NF 50.09 430.79 (SugarTab) Sucrose 7.34 63.16 Monostearate, FCC
(Crodesta F-160) Croscarmellose 5.32 45.79 Sodium, NF (Ac-Di-Sol) D&C Yellow #10 0.24 2.10 Lake Stearic Acid, NF 0.28 2.37 Totals 100.00 860.00 Other objects, advantages, features, modifications of this invention will be apparent to those of ordinary skill in this art. This invention is not limited except as set forth in the following claims.
Claims (63)
1. A composition comprising a mixture of a phytostanol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono-and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
2. The composition of claim 1, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
3. The composition of claim 1, wherein the phytostanol is selected from the group consisting of sitostanol, campestanol, 22,23 dihydrobrassicastanol, clionastanol and mixtures thereof.
4. The composition of claim 3, wherein the sitostanol is alpha-sitostanol or beta-sitostanol.
5. The composition of claim 2, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
6. The composition of claim 5, wherein said fatty alcohol is 1-octadecanol.
7. The composition of claim 2, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
8. The composition of claim 2, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
9. The composition of claim 1, comprising from about 10 to about 99.99 weight percent of said phytostanol and from about 0.01 to about 90 weight percent of said surfactant.
10. The composition of claim 9, comprising from about 40 to about 95 weight percent of said phytostanol and from about 5 to 60 weight percent of said surfactant.
11. The composition of claim 10, comprising about 95 weight percent of said phytostanol and about 5 weight percent of said surfactant.
12. A method of reducing cholesterol absorption in humans which comprises orally administering an effective amount of a mixture of a phytostanol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
13. The method of claim 12, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
14. The method of claim 12, wherein the phytostanol is selected from the group consisting of sitostanol, campestanol, 22,23 dihydrobrassicastanol, clionastanol and mixtures thereof.
15. The method of claim 14, wherein the sitostanol is alpha-sitostanol or beta-sitostanol.
16. The method of claim 13, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
17. The method of claim 16, wherein said fatty alcohol is 1-octadecanol.
18. The method of claim 13, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
19. The method of claim 13, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
20. The method of claim 12, comprising from about 10 to about 99.99 weight percent of said phytostanol and from about 0.01 to about 90 weight percent of said surfactant.
21. The method of claim 20, comprising from about 40 to about 95 weight percent of said phytostanol and from about 5 to 60 weight percent of said surfactant.
22. The method of claim 21, comprising about 95 weight percent of said phytostanol and about 5 weight percent of said surfactant.
23. The method of claim 12, wherein said mixture is orally administered in the form of chewable, effervescent, swallowable and coated tablets, capsules, soft gelatine capsules, syrup, fruit beverages, granule sachets, fruit gelatines, mini-sweets or sweets.
24. A method for reducing serum cholesterol levels comprising administering a mixture of a phytostanol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono-and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
25. The method of claim 24, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
26. The method of claims 24 or 25, wherein the mixture is administered orally.
27. The method of claim 24, wherein the phytostanol is selected from the group consisting of sitostanol, campestanol, 22,23 dihydrobrassicastanol, clionastanol and mixtures thereof.
28. The method of claim 27, wherein the sitostanol is alpha-sitostanol or beta-sitostanol.
29. The method of claim 25, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
30. The method of claim 29, wherein said fatty alcohol is 1-octadecanol.
31. The method of claim 25, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
32. The method of claim 25, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
33. The method of claim 24, comprising from about 10 to about 99.99 weight percent of said phytostanol and from about 0.01 to about 90 weight percent of said surfactant.
34. The method of claim 33, comprising from about 40 to about 95 weight percent of said phytostanol and from about 5 to 60 weight percent of said surfactant.
35. The method of claim 34, comprising about 95 weight percent of said phytostanol and about 5 weight percent of said surfactant.
36. A method for preparing a composition for the reduction of cholesterol absorption, comprising the step of mixing a phytostanol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono-and diglycerides, monosodium phosphate derivatives of mono- and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
37. The method of claim 36, wherein the mixing is conducted under elevated pressure.
38. The method of claim 37, wherein the mixing is conducted by roller compaction.
39. The method of claim 37, wherein the mixing is conducted in an extruder.
40. The method of claim 36, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
41. The method of claim 40, further comprising the step of heating said mixture of said phytostanol and said surfactants to a temperature that results in the formation of a melt.
42. The method of claim 41, further comprising the step of rapidly cooling said melt.
43. The method of claim 42, wherein liquid nitrogen is used for cooling.
44. A food product comprising a mixture of a phytostanol and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono-and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
45. The food product of claim 44, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
46. The food product of claim 44, wherein the phytostanol is selected from the group consisting of sitostanol, campestanol, 22,23 dihydrobrassicastanol, clionastanol and mixtures thereof.
47. The food product of claim 46, wherein the sitostanol is alpha-sitostanol or beta-sitostanol.
48. The food product of claim 45, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
49. The food product of claim 48, wherein said fatty alcohol is 1-octadecanol.
50. The food product of claim 45, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
51. The food product of claim 45, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
52. The food product of claim 44, comprising from about 10 to about 99.99 weight percent of said phytostanol and from about 0.01 to about 90 weight percent of said surfactant.
53. The food product of claim 52, comprising from about 40 to about 95 weight percent of said phytostanol and from about 5 to 60 weight percent of said surfactant.
54. The food product of claim 53, comprising about 95 weight percent of said phytostanol and about 5 weight percent of said surfactant.
55. A composition comprising a mixture of a phytostanol ester and a surfactant selected from the group consisting of sodium docusate, ammoniated glycyrrhizin, polyoxyethylene castor oil, polyethylene glycol, diacetyl lactic acid esters of mono- and diglycerides, diacetyl tartaric acid esters of mono- and diglycerides, monosodium phosphate derivatives of mono-and diglycerides, ethoxylated mono- and diglycerides, quillaja saponin, ethylene oxide propylene oxide block copolymers, vitamin E TPGS, hydroxylated lecithin and mixtures thereof.
56. The composition of claim 55, further comprising a surfactant selected from the group consisting of sodium salts of fatty acids, fatty alcohols, polyethylene glycol (8) stearate, polyethylene glycol (40) stearate, sucrose fatty acid esters, tween and mixtures thereof.
57. The composition of claim 55, wherein said fatty alcohol is selected from the group consisting of 1-decanol, 1-dodecanol, 1-tetradecanol, 1-hexadecanol, 1-octadecanol, 9-octadecen-1-ol, 1-eicosanol, 1-docosanol, 1-hexacosanol, 1-octacosanol, 1-triacontanol and mixtures thereof.
58. The composition of claim 57, wherein said fatty alcohol is 1-octadecanol.
59. The composition of claim 56, wherein said sucrose fatty acid ester is selected from the group consisting of sucrose stearate, sucrose distearate, sucrose palmitate and mixtures thereof.
60. The composition of claim 56, wherein said tween is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and polysorbate 85.
61. The composition of claim 55, comprising from about 10 to about 99.99 weight percent of said phytostanol ester and from about 0.01 to about 90 weight percent of said surfactant.
62. The composition of claim 61, comprising from about 40 to about 95 weight percent of said phytostanol ester and from about 5 to 60 weight percent of said surfactant.
63. The composition of claim 62, comprising about 95 weight percent of said phytostanol ester and about 5 weight percent of said surfactant.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16338299P | 1999-11-04 | 1999-11-04 | |
US60/163,382 | 1999-11-04 | ||
US19832600P | 2000-04-19 | 2000-04-19 | |
US60/198,326 | 2000-04-19 | ||
PCT/US2000/030417 WO2001032036A1 (en) | 1999-11-04 | 2000-11-03 | Cholesterol reducing stanol compositions, preparation and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2389605A1 true CA2389605A1 (en) | 2001-05-10 |
Family
ID=26859600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002389605A Abandoned CA2389605A1 (en) | 1999-11-04 | 2000-11-03 | Cholesterol reducing stanol compositions, preparation and method of use |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1225813A1 (en) |
JP (1) | JP2003520204A (en) |
AU (1) | AU1463601A (en) |
BR (1) | BR0015302A (en) |
CA (1) | CA2389605A1 (en) |
MX (1) | MXPA02004511A (en) |
WO (1) | WO2001032036A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ519268A (en) * | 1999-12-15 | 2004-12-24 | Mcneil Ppc Inc | Cholesterol lowering comestibles comprising policosanol (predominately octasanol) and sterol |
US6685961B1 (en) * | 2000-10-24 | 2004-02-03 | Banner Pharmacaps, Inc. | Colored gelatin-based formulations and method |
WO2003077680A1 (en) * | 2002-03-20 | 2003-09-25 | Eugene Science Inc. | Mixing powder of plant sterol and emulsifier, and method for preparing the same |
US6623780B1 (en) | 2002-03-26 | 2003-09-23 | Cargill, Inc. | Aqueous dispersible sterol product |
DE10253111A1 (en) * | 2002-11-13 | 2004-05-27 | Basf Ag | Powdered formulation used e.g. as food additive or pharmaceutical for preventing arteriosclerosis and hyperlipemia, contains phytosterol |
US20060035009A1 (en) * | 2004-08-10 | 2006-02-16 | Kraft Foods Holdings, Inc. | Compositions and processes for water-dispersible phytosterols and phytostanols |
US8360990B2 (en) | 2004-12-16 | 2013-01-29 | Senorx, Inc. | Biopsy device with aperture orientation and improved tip |
ZA200705739B (en) * | 2005-01-14 | 2009-01-28 | Unilever Plc | Sachets comprising plant sterol |
DE102005008445A1 (en) | 2005-02-24 | 2006-08-31 | Cognis Ip Management Gmbh | Sugary sterol solid dispersions |
US9254264B2 (en) | 2008-02-06 | 2016-02-09 | Biosuspensions Limited | Compositions and uses thereof |
JP5711671B2 (en) * | 2009-02-23 | 2015-05-07 | ナノルクス、インコーポレイテッドNanorx,Inc. | Policosanol nanoparticles |
EP2632437A4 (en) * | 2010-10-29 | 2014-03-19 | Univ Western Health Sciences | Ternary mixture formulations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62186936A (en) * | 1986-02-13 | 1987-08-15 | Asahi Denka Kogyo Kk | Emulsified or solubilized sterol composition |
US5244887A (en) * | 1992-02-14 | 1993-09-14 | Straub Carl D | Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof |
US6423363B1 (en) * | 1997-08-22 | 2002-07-23 | Lipton, Division Of Conopco, Inc. | Aqueous dispersion |
US6063776A (en) * | 1998-05-26 | 2000-05-16 | Washington University | Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same |
US6123978A (en) * | 1998-08-31 | 2000-09-26 | Mcneil-Ppc, Inc. | Stable salad dressings |
ES2204503T3 (en) * | 1999-02-03 | 2004-05-01 | Forbes Medi-Tech Inc. | METHOD FOR PREPARING MICROPARTICLES OF PHYTOSTEROLS OR PHYTOSTANOLS. |
-
2000
- 2000-11-03 WO PCT/US2000/030417 patent/WO2001032036A1/en not_active Application Discontinuation
- 2000-11-03 BR BR0015302-8A patent/BR0015302A/en not_active Application Discontinuation
- 2000-11-03 CA CA002389605A patent/CA2389605A1/en not_active Abandoned
- 2000-11-03 MX MXPA02004511A patent/MXPA02004511A/en unknown
- 2000-11-03 AU AU14636/01A patent/AU1463601A/en not_active Abandoned
- 2000-11-03 EP EP00976929A patent/EP1225813A1/en not_active Withdrawn
- 2000-11-03 JP JP2001534252A patent/JP2003520204A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2001032036A1 (en) | 2001-05-10 |
JP2003520204A (en) | 2003-07-02 |
MXPA02004511A (en) | 2002-10-11 |
EP1225813A1 (en) | 2002-07-31 |
AU1463601A (en) | 2001-05-14 |
BR0015302A (en) | 2003-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2388339A1 (en) | Cholesterol reducing sterol compositions, preparation and method of use | |
US6063776A (en) | Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same | |
US5932562A (en) | Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same | |
CA2332450A1 (en) | Esterified and subsequently hydrogenated phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like | |
CA2389605A1 (en) | Cholesterol reducing stanol compositions, preparation and method of use | |
US20030203854A1 (en) | Composition for effecting serum cholesterol levels | |
WO2007038596A2 (en) | Phytosterol nutritional supplements | |
KR100753729B1 (en) | Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester | |
AU2006263577B2 (en) | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease | |
EP2278890B1 (en) | Compositions of phytosterols with enhanced bioavailability | |
CN1450863A (en) | Cholesterol composition for reducing sterol compositions, preparation method of use | |
JP2004521941A (en) | Method for producing free-flowing powder containing water-dispersible sterols | |
KR100362025B1 (en) | Tumor-angiogenesis inhibitor and pharmaceutical composition | |
KR20220118504A (en) | composition for suppressing obesity | |
CN1479581A (en) | Cholesterol reducing stanol compositions, preparation and method of use | |
WO2005074720A1 (en) | Use and composition of a powder of high melting fatty substance to induce a prolonged satiety feeling | |
PL193796B1 (en) | Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same | |
AU2002316319A1 (en) | Method for manufacturing of free-flowing powder containing water-dispersible sterols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20040805 |